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7-methylguanosine (m7G) is present at mRNA caps
and at defined internal positions within tRNAs and
rRNAs. However, its detection within low-abundance
mRNAsandmicroRNAs (miRNAs)hasbeenhampered
by a lack of sensitive detection strategies. Here, we
adapt a chemical reactivity assay to detect internal
m7G in miRNAs. Using this technique (Borohydride
Reduction sequencing [BoRed-seq]) alongside RNA
immunoprecipitation, we identifym7Gwithin a subset
ofmiRNAs that inhibit cellmigration.Weshow that the
METTL1 methyltransferase mediates m7G methyl-
ation within miRNAs and that this enzyme regulates
cell migration via its catalytic activity. Using refined
mass spectrometry methods, we map m7G to a
single guanosine within the let-7e-5p miRNA. We
show that METTL1-mediated methylation augments
let-7 miRNA processing by disrupting an inhibitory
secondary structure within the primary miRNA tran-
script (pri-miRNA). These results identify METTL1-
dependent N7-methylation of guanosine as a new
RNA modification pathway that regulates miRNA
structure, biogenesis, and cell migration.
INTRODUCTION
Post-synthesis covalent modification of biological molecules is a
key aspect of intracellular signaling, and it is critically important
in many biological processes. RNA molecules, similar to pro-
teins, are subject to a vast array of post-synthesis covalent mod-
ifications, which together constitute the epitranscriptome. ToMolecular Cell 74, 1–13
This is an open access article unddate, >100 RNA modifications have been identified, which are
spread throughout every class of RNA and are evolutionarily
conserved throughout all kingdoms of life (Carell et al., 2012;
Machnicka et al., 2013).
RNA modifications have the potential to affect all RNA pro-
cesses, including splicing, stability, and localization (Roundtree
et al., 2017). Many RNA modifications have been identified by
mass spectrometry (MS), and complex epitranscriptomes of
tRNA and rRNA have been thoroughly studied. However, this
represents a mere snapshot of a much bigger picture, with the
clear majority of modifications remaining uncharacterized. This
is predominantly due to a lack of sensitive methodologies with
which to detect the modifications at a high resolution. Even
now, MS methodologies are largely unable to generate tran-
scriptome-wide modification profiles. However, a few very
recent analyses have used anti-modification antibodies (e.g.,
against N1-methyladenosine [Dominissini et al., 2016], N6-meth-
yladenosine [Dominissini et al., 2012], and 5-hydroxymethylcyto-
sine [Delatte et al., 2016]) or chemical reactivity of the modifica-
tion (for pseudouridine [Carlile et al., 2014; Schwartz et al., 2014],
m5C [Schaefer, 2015], and 2
0-O-methylation [Dai et al., 2017]).
Their results clearly suggest that many of the modifications iden-
tified on rRNA and tRNA are also present on other RNA classes.
Therefore, the development of epitranscriptomic methodologies
(e.g., new antibody and chemical methods coupled to next-
generation sequencing [NGS]) represents a bottleneck in deci-
phering the function of new RNA modifications.
Certain nucleotides, such as 7-methylguanosine (m7G),
display specific modification-dependent chemistries that can
be exploited to study their prevalence and transcript location.
m7G is present in eukaryotic mRNA 50 caps and at defined inter-
nal positions within tRNAs and rRNAs across all domains of life.
The best-characterized enzyme mediating internal m7G methyl-
ation is the TRMT8 yeast enzyme homolog METTL1 (methyl-
transferase-like 1), which, together with its co-factor WDR4, June 20, 2019 ª 2019 The Author(s). Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
AB
C
D
G H I J
FE
Figure 1. Detection of m7G in Specific miRNAs in A549 Cells
(A) Schematic of a novel chemical method to detect internal m7G RNA modification.
(B) Schematic representation of the procedure used to identify the m7G modified miRNAs in A549 cells.
(C) Immuno-dot blot of total decapped INPUT RNA (10%) or RNA immunoprecipitated with anti-m7G antibody or control immunoglobulin G (IgG).
(D) Immunoprecipitation with anti-m7G antibody enriches for m7G-containaing RNAs as determined bymass spectrometry (MS; see also Figure S1). The average
of two biological replicates ± SDs is shown.
(E) Scatterplot showing a high degree of consistency between the BoRed-seq approach and RIP-seq in detecting miRNAs harboringm7G (upper right quadrant).
Goodness of fit is calculated as R2 Pearson correlation coefficient.
(F) RNA immunoprecipitation with the anti-m7G antibody coupled to qRT-PCR was used to validate five m7G-containing miRNAs and four negative miRNAs,
which are identified in (E). The average of four biological replicates ± SDs is shown. The distributions of mean enrichments in m7G+ and m7G miRNAs are
significantly different, as evaluated by the two-tailed Wilcoxon text (*p < 0.05).
(G) Venn diagram showing the overlap betweenmiRNAs significantly enriched inm7G-RIP of A549 andCaco-2 cells, respectively (see also Figure S2). The p value
is obtained by Fisher’s exact test.
(H) Western blot showingMETTL1 protein levels in A549 cells infected withMETTL1-specific (sh1, sh2) or control (Scramble) tetracycline (TET)-inducible shRNAs
5 days after doxycycline treatment. A representative experiment of four independent biological replicates is shown.
(legend continued on next page)
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such as tRNAPhe (Alexandrov et al., 2002).
In contrast to deoxy-m7G, m7G in RNA is highly stable in
neutral aqueous solution (Kriek and Emmelot, 1964). Themethyl-
ation significantly alters the charge density of RNA, potentially
serving as a molecular handle, but it does not impair Watson-
Crick G:C base complementarity. It does, however, interfere
with non-canonical base pairing (i.e., Hoogsteen pairs), possibly
affecting the secondary structure of RNA. Although relatively
abundant, m7G has proved very difficult to study so far. Being
neutral to Watson-Crick base pairing, it does not interfere with
reverse transcription, rendering it invisible to detection by stan-
dard sequencing-based technologies.
microRNAs (miRNAs) are short single-stranded RNA mole-
cules (18–24 nucleotides [nt]) that target the RNA interference
silencing complex (RISC) to specific mRNAs. Their specificity
is mediated by partial base pairing to sequences predominantly
found in the 30 UTR of mRNAs (Bartel, 2009). This interaction
results in the decreased translation of the proteins they encode
and/or in the degradation of the mRNAs themselves (Fabian
et al., 2010; Ghildiyal and Zamore, 2009). To date, >1,000 human
miRNAs have been identified, and they are key regulators of
numerous physiological and pathological processes.
miRNA biosynthesis is complex and involves a multistep
pathway that can be regulated at many levels (Bartel, 2018),
including post-transcriptional modification of miRNA precursors
(Alarco´n et al., 2015; Xhemalce et al., 2012). miRNAs are synthe-
sized from larger transcriptsbyRNApolymerase II or III. These pri-
mary miRNA transcripts (pri-miRNAs) are then cleaved by DRO-
SHA to release hairpin-shaped RNAs called pre-miRNAs (Lee
et al., 2003), and further cleaved by DICER to generate a miRNA
duplex (Chendrimadaet al., 2005).CertainmiRNAscan formalter-
native secondary structures, such as G-quadruplexes, that can
interfere with their processing (Mirihana Arachchilage et al.,
2015; Pandey et al., 2015). However, little is known about the bio-
logical relevance of these structures in a physiological context.
Here, we develop two different but complementary high-
throughput sequencing strategies to identify miRNAs harboring
internal m7G modification. We show that METTL1 methylates a
specific subset of tumor suppressor miRNAs, including let-7,
to promote their processing from primary transcript to precursor
miRNA. Depletion of METTL1 causes gene expression and
phenotypic changes in a miRNA-dependent manner. We show
that m7G-modified miRNAs have a propensity to form G-quad-
ruplexes. We identify guanosine 11 as the m7G methylated
residue within let-7e-5p, and we show that methylation at this
position affects G-quadruplex formation, thereby promoting pro-
cessing of the precursor miRNA.
RESULTS
To detect N7-methylguanosine within low-abundant RNAs, we
adapted an existing strategy (Zueva et al., 1985) to allow the(I) Boxplot showing increasedm7G signal (as an average enrichment in both BoRe
upon inducible METTL1 knockdown, but not in miRNAs that are unchanged (=) o
(J) qRT-PCR showing the levels of let-7e-5p and miR-125a-5p in WT and METT
inactive (c.i.) exogenous METTL1 (Ex. METTL1).profiling of internal m7G in eukaryotic RNAs. In this reaction,
m7G residues are prone to nucleoside hydrolysis when reduced
by treatment with NaBH4. The resulting abasic sites can be re-
vealed by aniline-induced cleavage of the RNA chain by b-elim-
ination. This reaction is the basis of direct RNA sequencing
(RNA-seq) by the Maxam and Gilbert method (Peattie, 1979)
and has been used formappingm7G residues in highly abundant
rRNAs and tRNAs at single nucleotide resolution (Zueva et al.,
1985). We optimized the reaction conditions for the reduction
of mammalian total RNA in the absence of methylated carrier
RNA, which would interfere with the NGS analysis. As proof of
principle, reduced 18S rRNA was cleaved by aniline treatment
into two fragments, in agreement with the known position of
m7G (Piekna-Przybylska et al., 2008; Figure S1A).
The above strategy is not suitable for very short RNAs such
as miRNAs, because the resulting cleavage fragments would
be too small to be unequivocally mapped to the human tran-
scriptome. Therefore, we developed a new protocol, based
on the above, to detect m7G within miRNAs, which we refer
to as Borohydride Reduction (BoRed-seq) (Figure 1A). Total
RNA from a human lung cancer cell line (A549 cells) was
decapped, treated with NaBH4, and exposed to low pH to
generate abasic sites at positions harboring m7G. These sites
were exposed to a biotin-coupled aldehyde reactive probe
(N-(aminooxyacetyl)-n0-(D-biotinoyl) hydrazine; ARP) that cova-
lently binds to abasic RNA sites (Tanaka et al., 2011). Modified
RNAs were then pulled down using streptavidin beads, small
RNA libraries were prepared, and RNAs were identified by
high-throughput sequencing. Using this approach (Figure 1B),
a number of mature miRNAs likely to contain m7G were identi-
fied (Table S1).
To confirm the validity of this technique and to provide an in-
dependent verification of m7G-methylated miRNAs, we per-
formed an RNA immunoprecipitation sequencing (RIP-seq)
experiment using an antibody that recognizes m7G in RNA (Fig-
ure 1C). This antibody immunoprecipitates m7G-containing
RNAs, but not other methylated G-containing RNAs (as judged
by MS; Figures 1D and S1B–S1D), and it specifically enriches
m7G-containing 18S rRNA and tRNAs (Figures S2A and S2B).
RIP-seq with this antibody identified a second cohort of mature
miRNAs containing m7G (Table S2).
We then compared the results from the BoRed-seq and RIP-
seq approaches and found there was a significant overlap of
m7G-modified miRNAs detected by each technique (Figures
1E, upper right quadrant, S2C, and S2D). We regard these
miRNAs as high-confidence m7G-modified miRNAs (Table S3),
five of which were validated by RIP-qPCR analysis (Figure 1F).
m7G is found on miRNAs of any abundance, bearing no correla-
tion with any particular expression level (Figure S2E).
We extended these analyses to an unrelated colorectal cancer
cell line (Caco-2 cells), which expresses METTL1 at levels com-
parable to those observed in A549 cells. This identified signifi-
cantly overlapping m7G-modified miRNAs (Figures 1G andd-seq andm7G-RIP-seq; E) in miRNAs that are significantly downregulated (Y)
r upregulated ([). Statistical significance was calculated by the Wilcoxon test.
L1 knockdown A549 cells in the presence of either active (+) or catalytically
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Table 1. miRNAs Harboring METTL1-Dependent m7G
BoRed-Seq m7G-RIP-Seq
miRNA Log2Enrich FDR Log2Enrich FDR
hsa-let-7a-5p (im) 3.793 1.47E35 0.923 7.05E12
hsa-let-7b-3p 3.650 5.36E20 0.923 1.26E11
hsa-let-7b-5p (im) 3.848 5.38E40 1.756 1.25E27
hsa-let-7c-5p (im) 4.049 6.87E39 1.128 4.61E15
hsa-let-7e-5p (im) 3.357 5.77E30 2.149 6.00E32
hsa-miR-125a-5p (im) 0.921 3.76E03 0.575 3.46E03
hsa-miR-149-3p 3.227 2.37E02 2.306 3.03E14
hsa-miR-193a-5p 1.673 8.71E03 0.743 9.27E04
hsa-miR-23b-5p (im) 2.490 6.78E06 2.789 3.32E54
hsa-miR-320a (im) 1.924 4.26E11 1.336 1.07E14
hsa-miR-320b (im) 2.568 6.54E16 1.740 7.94E54
hsa-miR-320c (im) 3.465 1.81E20 2.066 3.88E50
hsa-miR-320d 2.968 1.84E09 2.217 4.53E59
hsa-miR-320e 2.794 1.15E02 1.460 1.89E09
hsa-miR-328-3p 1.669 8.85E03 1.260 2.17E15
hsa-miR-505-5p 2.830 3.12E02 2.274 1.52E13
hsa-miR-663a (im) 6.671 3.23E43 1.106 7.60E04
hsa-miR-760 3.142 5.18E04 2.258 1.93E31
hsa-miR-92b-3p 2.416 7.64E14 1.459 1.72E27
hsa-miR-92b-5p 4.302 1.06E30 0.805 1.84E07
Table shows m7G-modified miRNAs (from Figure 1E) whose expression
is downregulated upon METTL1 knockdown. miRNAs highlighted with
superscript (im) have been linked to the inhibition of cellular migration
(Zhang et al., 2011). FDR, false discovery rate.
Please cite this article in press as: Pandolfini et al., METTL1 Promotes let-7 MicroRNA Processing via m7G Methylation, Molecular Cell (2019), https://
doi.org/10.1016/j.molcel.2019.03.040S2F; Table S4), suggesting that m7Gmodification of miRNAs is a
general and conserved phenomenon.
Deposition of m7G in tRNA is catalyzed, at least in part, by
METTL1. We therefore asked whether any of our high-confi-
dence m7G-containing miRNAs are affected by METTL1 deple-
tion. Knockdown ofMETTL1 in A549 cells (Figures 1H and S2G)
followed by small RNA-seq revealed that significantly downregu-
lated miRNAs are more enriched in m7G, compared to miRNAs
that are upregulated or unchanged (Figure 1I; Table S5). Similar
effects were also observed in Caco-2 cells (Figure S2H). The
reduced levels of m7G-containing miRNAs are rescued by the
expression of wild-type (WT) METTL1 but not by a catalytically
inactive version (Figures S2I and S2J) of the enzyme (Figure 1J).
Interrogation of the m7G-containing miRNAs downregulated
upon METTL1 knockdown (Table 1) shows that 50% (10/20) of
them have been previously functionally linked to the inhibition
of cell migration (Zhang et al., 2011). This raised the possibility
that METTL1may control cell migration via regulation of a subset
of miRNAs, including the let-7 family (Lee and Dutta, 2007). To
explore this possibility, we first tested whether METTL1 affects
the migration of A549 cells. Knockdown ofMETTL1 significantly
increases their migratory capacity (Figures 2A and 2B) without
affecting cellular proliferation (Figure 2C) or overall mRNA trans-
lation levels (Figure S2K). Notably, the increased migration is
rescued by the expression of WT METTL1, but not by a catalyt-
ically inactive version of the enzyme (Figure S3A). These results4 Molecular Cell 74, 1–13, June 20, 2019suggest that METTL1 specifically influences cell migration via
m7G methylation of miRNAs.
To further explore this possibility, we performed a global gene
expression analysis to identify transcripts affected by the deple-
tion of METTL1 (Figure 2D; Table S6). This revealed 254 upregu-
lated and 60 downregulated transcripts. Gene Ontology analysis
indicated the upregulation of pathways involved in cellular
migration (Figures 2E, and S4B–S4E; Table S7), in agreement
with our phenotypic characterization of METTL1 knockdown
cells (Figures 2A and 2B).
We then asked whether METTL1-regulated transcripts are
also targets of the m7G-modified miRNAs. In silico-predicted
mRNA targets for these miRNAs are differentially expressed
upon METTL1 knockdown, whereas mRNA targets of control
miRNAs are not (Figure 2F). We confirmed these findings using
an unbiased approach that identified let-7(5p) seed sequence
as the most significantly enriched in upregulated mRNAs (Fig-
ure S3F), a number of which are individually shown in Figure S3G.
The presence of the let-7 target sequence within the 30UTR of
mRNAs represents the strongest predictive factor for their upre-
gulation upon METTL1 knockdown (Figure S3H).
The above results indicate that many of the genes involved in
cell migration and upregulated upon METTL1 depletion are tar-
gets of METTL1-dependent miRNAs. This suggests that METTL1
regulates gene expression via the control of miRNA function. To
investigate this possibility, we focused on HMGA2, one of the
most upregulated transcripts following METTL1 depletion, and
whose 30 UTR is significantly enriched for evolutionarily
conserved target sites of several m7G-containing miRNAs,
including let-7(5p), miR-125(5p), and miR-92(3p) (Figure 3A;
odds ratio [OR] = 5.46, p = 0.001). First, we confirmed that
METTL1 knockdown increases HMGA2 mRNA expression and
protein levels in both A549 cells (Figures 3B and 3C) and
Caco-2 cells (Figures S4A and S4B). Second, we confirmed that
HMGA2 mRNA is not m7G modified itself by performing
BoRed-qPCR and RIP-qPCR (Figure S4C).
To demonstrate that the effect of METTL1 was mediated, at
least in part, by a miRNA pathway, we generated a stable
A549 cell line containing a reporter construct consisting of the
30 UTR of Hmga2 linked to the coding sequence of luciferase.
Knock down ofMETTL1 in this reporter line increases luciferase
activity, confirming that the 30 UTR of HMGA2 confers respon-
siveness to METTL1 (Figures 3D and 3E). To confirm that
METTL1 regulation of the 30 UTR of HMGA2 is mediated through
the action ofmiRNAs, we concentrated on let-7, which has seven
binding sites within this 30 UTR. Deletion of the let-7 seed
sequences from the 30 UTR leads to increased luciferase activity
and uncouples it from METTL1 regulation (Figures 3E and S4D).
Figure 3F shows that the introduction of mature let-7e-5p
miRNA into A549 cells reduced HMGA2 protein expression as
expected (Mayr et al., 2007). Transfection of mature let-7e
miRNA reverts the upregulation of HMGA2 protein caused by
METTL1 depletion (Figure 3F). Expression of a short hairpin
RNA (shRNA)-resistant version of WT METTL1 also reverts
HMGA2 upregulation due toMETTL1 depletion, and this requires
the catalytic activity of the methyltransferase (Figure 3G). These
data confirm that METTL1 methyltransferase activity regulates
the expression of HMGA2 in a let-7-dependent manner.
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Figure 2. METTL1 Inhibits Cellular Migration of A549 Cells
(A) A migration assay was performed for 7 h using cells infected with METTL1-specific (sh1, sh2) or control (Scramble) TET-inducible shRNAs 5 days after
doxycycline treatment.
(B) Results from (A) were quantitated and plotted, as indicated. The plot shows the average of six biological replicates ± SDs (***p < 0.001, two-tailed t test).
(C) A proliferation assay was initiated 4 days after doxycycline treatment of cells infected with METTL1-specific (sh1, sh2) or control (Scramble) TET-inducible
shRNAs. The average of four biological replicates ± SDs is shown.
(D) Global gene expression analysis of cells infected withMETTL1-specific (sh1) or control (Scramble) TET-inducible shRNAs 5 days after doxycycline treatment.
log2 fold change was plotted against average log2 expression. Significantly upregulated (red) and significantly downregulated (blue) transcripts are indicated. See
also Figure S3.
(E) Gene Ontology analysis of gene expression changes following METTL1 knockdown identifying upregulated Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways involved in cellular migration (red).
(F) log2 fold change in the expression of predicted targets of the indicated miRNAs uponMETTL1 knockdown. Each pair of boxplots compares the fold change of
mRNAs that are targets (red) or not (gray) of a single specific miRNA. Statistical significance was calculated by the Wilcoxon test.
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METTL1. We used UV cross-linking and immunoprecipitation
(CLIP) to confirm in our system previous findings (Bao et al.,
2018) thatMETTL1 binds directly tomiRNA precursors, including
pri-let-7e and pri-miR-125a hairpins (Figures 4A and S4E). To
date, there are two known methylations of miRNA: m6A cata-
lyzed byMETTL3 (Alarco´n et al., 2015) and 50-phosphate methyl-
ation catalyzed by BCDIN3D (Xhemalce et al., 2012). In both
cases,methylation regulatesmiRNAprocessing. To test whether
METTL1 may also be involved in such a pathway, we asked
whether it regulates the processing of m7G-containing miRNAs.
Depletion of METTL1 significantly reduced the levels of the pre-
mature and mature forms of let-7e-5p and miR-125a-5p,
whereas their primary transcripts were unaffected (Figures 4B,
4C, and S4F). This is unlikely to be due to a general defect in pro-
cessing since METTL1 depletion does not affect the levels of
various miRNA processing factors (Figure S4G).
The above findings indicate that METTL1 activity is required
for pri- to pre-processing of miRNAs, implying that pri-miRNAs
are directly m7G modified by METTL1 and that the modification
is subsequently retained through to the mature miRNA (Fig-ure S4H). m7G RIP experiments show that pri-miRNAs are
enriched in m7G, which decreases upon METTL1 knockdown
(Figures 4D, S4I, and S4J).
To further demonstrate the METTL1-dependent effect on
miRNA processing, we used an in vitro assay (Lee et al., 2002)
to test the efficiency of cellular extracts to process a radioactive
pri-let-7e transcript into precursor and mature miRNAs. Cellular
extracts devoid of METTL1 process precursor transcripts less
efficiently than control extracts (Figure S5A). Thus, METTL1 is
required for the efficient processing of target miRNAs such as
let-7.
To confirm that pri-let-7e is directly methylated by METTL1,
we performed an in vitro methyltransferase assay using a pre-
assembled recombinant METTL1/WDR4 complex (Figure S5B)
and pri-let-7e hairpin oligonucleotides, tRNAPhe, and an unre-
lated negative control miRNA (cel-miR-67 hairpin) as substrates.
Using MS, we detected m7G in let-7e RNA and tRNAPhe, but not
in the control miRNA (Figures 4E and S5C).
To directly assess whether m7G affects miRNA processing,
we prepared radiolabeled m7G containing pri-let-7e RNA, as
shown in Figure 4F. Briefly, radioactive pri-let-7e hairpinMolecular Cell 74, 1–13, June 20, 2019 5
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Figure 3. METTL1 Catalytic Activity Regulates HMGA2 Expression in a let-7-Dependent Manner
(A) Schematic of HMGA2 30 UTR showing the enrichment of evolutionarily conserved target sites of several m7G-containing miRNAs (OR = 5.46, p = 0.001).
(B) HMGA2 expression was measured by qRT-PCR in A549 cells infected with METTL1-specific (sh1, sh2) or control (Scr) TET-inducible shRNAs 5 days after
doxycycline treatment. The average of six biological replicates ± SDs is shown (***p < 0.001, two-tailed t test).
(C) Western blot showing METTL1, HMGA2, and b-tubulin protein levels in A549 cells infected with METTL1-specific (sh1, sh2) or control (Scramble)
TET-inducible shRNAs 5 days after doxycycline treatment. Two representative biological replicates of a total of four are shown.
(D)Western blot showingMETTL1 downregulation upon transfection withMETTL1-specific siRNAs in A549 cells stably expressing a luciferase cDNAwithHmga2
30 UTR. Two independent transfections of a total of four replicates are shown.
(E) Luciferase fluorescence levels uponMETTL1 downregulation in A549 cells stably expressing a luciferase cDNAwithHmga2 30 UTR as a reporter. Red and gray
bars indicate luciferase levels in the presence of either WTHmga2 30 UTR or of a variant in which all 7 let-7 seed sequences have been mutated, respectively. The
plot shows the average of four independent transfections ± SDs (***p < 0.001, two-tailed t test).
(F) Western blot showing the rescue of HMGA2 upregulation upon transfection with let-7e-5pmaturemiRNA inMETTL1 knockdown A549 cells. Two independent
transfection replicates of a total of four are shown.
(G) Western blot showing the rescue of HMGA2 upregulation upon the overexpression of WT, but not catalytically inactive METTL1, in A549METTL1 knockdown
cells. Two representative biological replicates of a total of five independent infections are shown.
See also Figure S4.
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doi.org/10.1016/j.molcel.2019.03.040RNA was methylated in vitro by incubation with the METTL1/
WDR4 complex, and m7G containing RNA was enriched via
RIP. The resulting methylated and non-methylated (control)
pri-miRNAs were then subjected to a DROSHA processing
assay. The results indicate that m7G methylated pri-let-7e
RNA was more efficiently processed by DROSHA in vitro
(Figure 4G).
To probe the mechanism by which m7G methylation of let-7e
affects its processing in vivo, we sought to identify the position of
the methylation site within the let-7emiRNA. We set up spectral
sequencing of RNAmethylation and applied it to mature miRNAs
purified from A549 cells. This targeted MS method allows the
mapping of modification sites within a specific sequence at sin-
gle base resolution. This approach highlighted one methylated
guanosine at position 11 (G11) of let-7e-5p (Figures 5A, 5B,
and S5D), which is also required for efficient in vitro methylation
of let-7e (Figure S5E).
G11 is part of a short 16-nt-long G-rich sequence of the form
G2+N4G2+N4G2+N4G2+, where N is any base. This type of motif
is known to fold into the alternative Hoogsteen base-paired
G-quadruplex structure (Kwok et al., 2016a). It is noteworthy6 Molecular Cell 74, 1–13, June 20, 2019that the formation of a G-quadruplex structure has been docu-
mented in three miRNA precursors, namely miR-92b (Mirihana
Arachchilage et al., 2015), miR-149 (Kwok et al., 2016b), and
let-7e (Pandey et al., 2015). According to our previous results,
all of these miRNAs are both m7Gmodified and METTL1 depen-
dent (Table 1), suggesting that G-quadruplex formation may be
involved in the regulation of m7G-modified miRNAs.
To explore the connection between G-quadruplexes and
m7G, we analyzed the base composition of m7G harboring miR-
NAs, assessing the potential enrichment of G-quadruplexmotifs.
We found that m7G-modified miRNAs are characterized by a
bias in nucleotide content toward increased G-richness (Fig-
ure S6A) and G-skewness (Figure 5C). These observations sug-
gest that m7G harboring miRNAs display sequences with the
propensity to form G-quadruplexes. Moreover, using a G-quad-
ruplex-predicting algorithm, we found that miRNAs containing at
least one predicted G-quadruplex are significantly enriched in
m7G (Figures 5D and S6B). The G-quadruplexes are predicted
to fold at a very similar relative position within different m7G-con-
taining miRNA hairpins (Figure 5E), which overlaps the 50 site of
pri-miRNA (DROSHA) cleavage. Overall, these analyses suggest
A B
C D E
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Figure 4. METTL1 Directly Modifies let-7e pri-miRNA and Regulates Its Processing
(A) CLIP-qPCR using a METTL1-specific antibody or a non-specific IgG. The levels of immunoprecipitated pri-let-7e and pri-mir-125a hairpins are shown. The
average of two independent immunoprecipitation reactions ± SEMs is shown (*p < 0.05, two-tailed t test).miR-148a is shown in Figure S4E as a negative control.
(B) qRT-PCR showing the levels of either LET7E/125A primary transcript (blue) or let-7e andmiR-125a precursors (gray) uponMETTL1 knockdown in A549 cells.
The average of five to six independent biological replicates ± SDs is shown (*p < 0.05, **p < 0.01, two-tailed t test).
(C) qRT-PCR quantification of let-7e-5p and miR-125a-5p upon METTL1 knockdown. The average of five independent biological replicates ± SDs is shown
(**p < 0.01, ***p < 0.001, two-tailed t test). miR-148a-3p is shown in Figure S4F as a negative control.
(D) m7G RNA immunoprecipitation and qRT-PCR of LET7A3, LET7B, and LET7E/125A primary transcripts in A549 cells uponMETTL1 knockdown. The average
of three independent biological replicates ± SEMs is shown (*p < 0.05, **p < 0.01, ***p < 0.001, two-tailed t test).
(E) In vitro methylation reaction using recombinant METTL1/WDR4 pre-assembled complex on let-7e or cel-miR-67 primary hairpin (negative control). MS
analysis shows specific m7G methylation of the let-7e hairpin. The average of three independent experiments ± SDs is shown.
(F) Experimental strategy to obtain radiolabeled, m7G-modified pri-let-7e (IVm7G-pri). The histogram shows the fraction of RNA recovered by m7G-RIP after
in vitro methylation with METTL1/WDR4, as evaluated by scintillation counting (***p < 0.001, two-tailed t test).
(G) In vitro processing assay of pri-let-7e: control (Ctrl) or in vitro methylated pri-miRNAs were incubated in the presence of immunoprecipitated DROSHA.
Autoradiography reveals that IVm7G-pri undergoes more efficient processing, yielding the expected cleavage pattern shown in the illustration. The histogram
shows the relative quantification of the resulting pre-let-7e from four samples obtained in two independent experiments (*p < 0.05, two-tailed t test). Autora-
diography images are composites of different molecular weight regions and exposure times. Full, unprocessed images are deposited on Mendeley Data.
See also Figure S5.
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Figure 5. G-Quadruplexes Mark m7G-Containing miRNAs
(A and B) Spectral sequencing of in vivo let-7e-5p showing unmodified (A) and methylated 50-AGGAGGU-30 (B) fragments, obtained following RNase A digestion
of a miRNA fraction isolated from A549 cells (see also Figure S5).
(C) Boxplot showing the maximum G-score, a quantitative estimation of G-richness and G-skewness (see Method Details for definition), in primary hairpins of
either unmodified or m7G containing miRNAs (***p < 0.001, Wilcoxon test).
(D) Boxplot showing the enrichment of miRNAs, grouped according to the propensity of their primary hairpins to form G-quadruplexes (***p < 0.001,
Wilcoxon test).
(E) Metagene plot showing pri-miRNA cleavage site distribution (top) and the predicted stability of G-quadruplexes (center), and double strand (bottom) across
primary hairpins of unmodified (gray) or m7G-modified miRNAs (blue).
(F) Denaturation experiments of let-7e primary hairpin in the presence of 100 mM KCl followed by circular dichroism at 263 or 210 nm show two transitions
demonstrating that let-7e exists as a mixture of two distinct structures in equilibrium in solution (top). The first structure melts at 48.5C–50.6C, while the second
one is more stable (75.9C–73.6C).
(G) Scheme showing the predictedG-quadruplex (rG4, pink) within the pri-let-7e hairpin. In red are shown the guanosines predicted to be involved in the formation
of the quadruplex motif. Arrows mark the cleavage sites of let-7e-5p processing. The asterisk indicates the position of m7G.
See also Figure S6.
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lation of miRNA activity.
To support a role for G-quadruplex formation in the processing
of pri-let-7e, we carried out a biophysical analysis of the short
16-nt-long G-rich sequence, referred to as rG4-let-7e. Using
circular dichroism (CD), we found that the CD spectrum of
rG4-let-7e is cation dependent and is characterized by a
maximum ellipticity at 263 nm and a minimum ellipticity at
240 nm (Figure S6C). This observation is consistent with
G-quadruplex formation (Kypr et al., 2009). Denaturation exper-8 Molecular Cell 74, 1–13, June 20, 2019iments revealed a potassium-dependent transition at 48.1C
(Figure S6C). We then assessed the ability of this sequence to
fold into a G-quadruplex in the context of pri-let-7e. The CD
spectrum of pri-let-7e also displayed a maximum at 263 nm
and a local minimum at 240 nm, but with an additional minimum
at 210 nm indicative of a more complex structure (Figure S6D).
Denaturation experiments of pri-let-7e, followed by CD spec-
troscopy at 263 or 210 nm in the presence of KCl, revealed
two transitions indicating the presence of two structures in equi-
librium (Figure 5F). While the second transition is centered
A B C
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Figure 6. m7G Position Is Essential for let-7e Quadruplex:Stem-Loop Equilibrium and Promotes miRNA Processing
(A) Schematic representation of a guanine tetrad, highlighting Hoogsteen base pairing involving the N7 of guanosine that stabilizes the G-quadruplex structure,
together with a stabilizing monovalent cation (M+, usually potassium). Both 7-methylguanosine and 7-deaza-guanosine are able to destabilize the hydrogen bond
involving N7.
(B) Illustration depicting the pri-miRNA hairpins used in the following experiments.
(C) Thermal denaturation studies of RNA oligonucleotides as described in (B). While GG-to-DAG-DAGmutation at the D1 position does not significantly affect the
contribution of G4 in the G4:stem-loop equilibrium, GG-to-DAG-DAGmutation at the D1 position and a single G11-to-DAGmutation affect the contribution of rG4
in the structural equilibrium by shifting it toward the hairpin form.
(D) First derivative plot of the denaturation experiment in (C) helps visualize the decrease in rG4 contribution to the equilibrium (red arrow).
(E) qRT-PCR showing the levels of let-7e-5p 72 h after transfection with either WT, D1, D2, or G11 oligonucleotides. The average of six independent
transfections ± SDs is shown (**p < 0.01, ***p < 0.001, two-tailed t test).
(F) Western blot showing the rescue of HMGA2 upregulation upon transfection of D2, but not WT let-7e primary hairpin in A549METTL1 knockdown cells. Two
representative biological replicates of a total of three independent experiments are shown.
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doi.org/10.1016/j.molcel.2019.03.040around75C and correspond to the expected hairpin structure,
a first transition was observed at 48C, similar to the melting
transition of rG4-let-7e, and may correspond to the formation
of the rG4-let-7e-quadruplex structure. To support this point,
we introduced G-to-A mutations in pri-let-7e at positions that
are expected to destabilize the rG4-let-7e-quadruplex (Fig-
ure S6E). We found that G-to-A mutants display single-phase
melting curves with transitions >70C (Figure S6F). This result
demonstrates that G-to-A mutations in pri-let-7e impede
G-quadruplex formation.
We hypothesized that m7Gmay affect the stability of G-quad-
ruplexes in vivo by disrupting the N7 H-bonds and Hoogsteen
base pairing while preserving Watson-Crick base pairing (Fig-
ure 6A). To support this hypothesis, we used 7-deaza-deoxygua-
nosine (DAG) as a mimic of m7G, since synthesis of
m7G-containing oligonucleotides is currently unavailable and
because, like m7G, DAG weakens secondary structures sup-
ported by Hoogsteen base pairing (Figure 6A; Ro¨mmler et al.,
2013). We found that the rG4-let-7e quadruplex structure con-
taining a single G-to-DAG substitution at the G11 position wassignificantly less stable than the WT sequence (Figure S6C).
We then generated G-to-DAG mutant versions of pri-let-7e (Fig-
ure 6B). While the D1 and D2 oligonucleotides displayed two
G-to-DAG mutations at G4-G5 and G11-G12, respectively, one
oligonucleotide bears a single G-to-DAG mutation at position
G11. Denaturation experiments followed by CD spectroscopy
were performed to assess the quadruplex:stem-loop equilibrium
within pri-let-7e and the contribution of each guanosine to
pri-let-7e folding (Figures 6C and 6D). We observed that muta-
tion of G11 (in both D2 and G11 mutants) affects the folding of
pri-let-7e by shifting the structural equilibrium toward the canon-
ical stem-loop structure. In contrast, mutating G4 and G5 (D1
mutant) did not significantly affect the structural equilibrium.
These results suggest that the methylation of G11 favors the
stem-loop structure of let-7e.
We next used the DAG-containing pri-let-7e hairpin oligonu-
cleotides to establish whether the induced change in structure
affects the processing of the precursor RNAs in vivo. We trans-
fected either WT or the DAG-containing oligonucleotides into
A549 cells and we measured the levels of mature let-7e-5p byMolecular Cell 74, 1–13, June 20, 2019 9
Figure 7. Role of m7G in miRNA Biogenesis
Proposed model of the role of METTL1-mediated m7G in promoting miRNA
processing and suppressing migration phenotype.
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D2 andWT oligonucleotides into A549METTL1 knockdown cells
andmeasured the levels of HMGA2 by immunoblotting. In agree-
ment with the biophysical observations, the D2 oligonucleotides,
containing G11 DAG, were more efficiently processed than
either WT let-7e or D1 oligonucleotides (Figure 6E). Finally, the
D2 oligonucleotide effectively rescued HMGA2 expression in
the absence of METTL1, whereas the WT did not (Figure 6F).
Overall, our data suggest that the methylation of pri-let-7e at
G11 promotes its processing via disruption of local G-quadru-
plex structures.
DISCUSSION
In the present study, we use two independent unbiased tech-
niques to demonstrate that a subset of miRNAs harbors internal
m7G modification. We find that these are functionally related,
tumor-suppressive miRNAs, and they include the let-7 family.
We show that m7G promotes the processing of their precursor
RNAs and that METTL1-dependent methylation is required to
suppress cellular migration. Furthermore, we developed a new
MS approach to identify m7G within a sequence-specific
context using RNA purified from cells. This allowed us to pinpoint
the modification to G11 of the mature let-7e-5p. We show that
pri-let-7e can adopt two alternative conformations, which are
consistent with a G-quadruplex structure and a canonical
stem-loop. The G11 position has previously been implicated in
the formation of a G-quadruplex structure (Pandey et al.,10 Molecular Cell 74, 1–13, June 20, 20192015), and we confirm the presence of this G-quadruplex in
let-7e. We show that the substitution of G11 with DAG affects
the quadruplex:stem-loop equilibrium within pri-let-7e and
mimics the effects due to m7G.
The presence of m7G in miRNAs strongly correlates with their
predicted tendency to adopt G-quadruplex structures. Such
structures are known to be inhibitory to miRNA processing (Mir-
ihana Arachchilage et al., 2015; Pandey et al., 2015), which is
consistent with our findings that the G-quadruplex motif in let-
7e overlaps the DROSHA cleavage site. Our data suggest a
model in which METTL1-mediated deposition of m7G within
G-rich regions destabilizes G-quadruplexes, thereby promoting
their processing from pri- to pre-miRNA (Figure 7).
While this manuscript was under revision, Gregory and col-
leagues (Lin et al., 2018) reported thatMETTL1 knockout mouse
embryonic stem cells possess defective mRNA translation at a
global level. In our system, by using an inducible knockdown
approach to reduce the levels of METTL1, we did not dramati-
cally affect the levels of m7G in tRNAs (Figure S2G). This is
consistent with our ribosome profiling results in normal versus
METTL1-depleted cells, which showed no significant effect
on overall translation (Figure S2K). Therefore, our inducible
approach allowed us to dissect new, orthogonal, m7G-depen-
dent pathways, uncoupling them from the effects of tRNA.
G-quadruplexes and other alternative structures involving
non-Watson-Crick base pairing have been described in other
classes of RNA, including mRNA (Bugaut and Balasubramanian,
2012); there they are proposed to induce ribosome stalling,
thereby inhibiting translation (Endoh et al., 2013). We speculate
that m7G represents a general way of destabilizing such struc-
tures, counteracting their effects. Thus, a comprehensive under-
standing of the m7G modification pathways will be instrumental
in deciphering the roles that Hoogsteen-based structures play in
physiological and pathological settings.
Only two other miRNA methylations have been identified in
miRNAs, m6A and 50-methyl phosphate (Alarco´n et al., 2015;
Xhemalce et al., 2012). However, these two modifications
show features that are different from the m7G features charac-
terized here. On the one hand, m6A enhances processing of
many, if not all, miRNAs in breast cancer cells, and can be
regarded as a general mechanism; this methylation promotes
the binding of DROSHA to the primary miRNA. On the other
hand, 50-methyl phosphate represses the processing of
miR-145 by inhibiting the binding of DICER to the pre-miRNA.
Here, we show that m7G promotes miRNA processing in a
unique manner, by directly affecting the secondary structure of
a specific set of pri-miRNAs that share a common functional
signature: suppression of cell migration.
The model proposed here could represent a widespread
molecular mechanism to safeguard the levels and activity of
important tumor-suppressive G-rich miRNAs. In this scenario,
the formation of G-quadruplexes is a ‘‘side effect’’ of the miRNA
sequence, and the m7G pathway is required to maintain
pre-miRNAs in a functional state. Alternatively, but not mutu-
ally exclusively, the presence of G-quadruplexes itself may
represent a novel additional layer of regulation to control
functionally related miRNAs, which, for example, inhibit cell
migration.
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doi.org/10.1016/j.molcel.2019.03.040Many mechanisms control cell migration and tumor invasive-
ness, and one of themost important drivers is the AKT oncogenic
signaling pathway (Irie et al., 2005). Notably, AKT has been
shown to directly phosphorylate METTL1 to inhibit its enzymatic
activity (Cartlidge et al., 2005). Given the findings presented
here, it is likely that the hyperactivation of AKT in cancer would
reduce the levels of m7G-containing tumor-suppressive
miRNAs, including the let-7 miRNA family. This family in partic-
ular inhibits the progression and invasiveness of numerous
tumors, including lung cancer, by regulating the expression of
key oncogenes such as RAS, MYC, and HMGA2 (Balzeau
et al., 2017). The control of let-7 family members by the m7G
pathway may represent a common mechanism to modulate
their expression and therefore activity. Beyond cancer, let-7 is
implicated in neurodegenerative diseases, such as Alzheimer’s
disease, in which it is significantly upregulated (Lehmann et al.,
2012). Furthermore, low levels of let-7 have been shown to
improve tissue repair through reprogramming cellular meta-
bolism (McDaniel et al., 2016; Shyh-Chang et al., 2013). There-
fore, direct targeting of METTL1 could represent a valid and
unexplored therapeutic strategy in these pathological contexts.
This report identifies the m7G pathway as a novel regulator of
miRNA function. Considering the interest in miRNA as targets
and tools in therapeutic intervention (Chakraborty et al., 2017),
our findings could be exploited in many miRNA-related disease
settings to open up new therapeutic avenues.STAR+METHODS
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Anti-m7G Mouse Monoclonal MBL (RN017M) RRID: AB_2725740
Anti-METTL1 Rabbit Polyclonal Abcam (ab157097) RRID: AB_2725741
Anti-METTL1 Sheep Polyclonal (for IP) MRC PPU (588192) RRID: AB_2725742
Anti-HMGA2 Rabbit Polyclonal Abcam (ab202387) RRID: AB_2725743
Anti b-Tubulin Rabbit Polyclonal Abcam (ab6046) RRID: AB_2210370
IgG Rabbit Isotype Control Abcam (ab171870) RRID: AB_2687657
Anti-FLAG tag Mouse Monoclonal Sigma-Aldrich (F1804) RRID: AB_262044
Anti-6xHIS tag Rabbit Polyclonal Abcam (ab9108) RRID: AB_307016
Anti-Myc tag Mouse Monoclonal Abcam (ab32) RRID: AB_303599
Anti-Rabbit IgG HRP-conjugated Goat Polyclonal Abcam (ab6721) RRID: AB_955447
Anti-Mouse IgG HRP-conjugated Goat Polyclonal Dako (P0447) RRID: AB_2617137
Bacterial and Virus Strains
TOP10 Chemically Competent E. coli Thermo Fisher Cat# C404003
Chemicals, Peptides, and Recombinant Proteins
1,1,1,3,3,3-Hexafluoropropan-2-ol Apollo Scientific Cat# PC0877
1,4-Dithiothreitol Thermo Fisher Cat# P2325
2-Mercaptoethanol Sigma-Aldrich Cat# M3148
7-methylguanosine triphosphate Sigma-Aldrich Cat# M6133
Acetic Acid Fisher Scientific Cat# A/0400/PB17
Acetonitrile Fisher Scientific Cat# 10407440
Antarctic Phosphatase NEB Cat# M0289S
Adenosine 50-Triphosphate NEB Cat# P0756S
Benzonase Sigma-Aldrich Cat# E1014-25KU
Boric Acid BDH Lab. Supplies Cat# 100584S
Bovine Serum Albumin NEB Cat# B9000S
Cacodylic acid Sigma-Aldrich Cat# C0125
CapCLIP Acid Pyrophosphatase CellScript Cat# C-CC15011H
Chloroform Fisher Scientific Cat# C/4960/15
Cycloheximide Sigma-Aldrich Cat# C7698
Deoxycholic acid Sigma-Aldrich Cat# D2510
DNAse I Qiagen Cat# 79254
Doxycycline Clontech Cat# 8634-1
Ethylenediaminetetraacetic Acid Fisher Scientific Cat# D/0700/53
Ethanol VWR Cat# 20820.327
Ethidium Bromide Sigma-Aldrich Cat# E1510
Fibronectin Sigma-Aldrich Cat# F2006
Formaldehyde 37% Sigma-Aldrich Cat# 252549
Formic acid Fisher Scientific Cat# 10596814
G418 disulphate Melford Cat# G0175
Glycogen Roche Cat# 10901393001
HEPES Melford Cat# B2001
KCl Sigma-Aldrich Cat# P9333
LiCl Sigma-Aldrich Cat# L-4408
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Lipofectamine 2000 Thermo Fisher Cat# 11668019
Lithium Hydroxide Sigma-Aldrich Cat# 442410
Methanol VWR Cat# 20846.326
METTL1/WDR4 Recombinant complex Evotec (Ad hoc preparation)
MgCl2 Sigma-Aldrich Cat# M-0250
N-(aminooxyacetyl)-N’-(D-Biotinoyl) hydrazine Thermo Fisher Cat# A10550
NaCl Sigma-Aldrich Cat# S7653
NheI NEB Cat# R3131S
NotI NEB Cat# R3189S
NP40 Sigma-Aldrich Cat# I3021
Phenylmethanesulfonyl fluoride Sigma-Aldrich Cat# P7626
Phosphocreatine disodium salt hydrate Sigma-Aldrich Cat# P7936
Phosphodiesterase 1 Sigma-Aldrich Cat# P3243-1VL
Polybrene Sigma-Aldrich Cat# 107689
Protease Inhibitor Complete tablets, EDTA-free Roche Cat# 11836170001
Proteinase K NEB Cat# P8107S
Puromycin Invivogen Cat# ant-pr-1
Qiazol Qiagen Cat# 79306
RNAse A Thermo Fisher Cat# EN0531
RnaseOUT Ribonuclease Inhibitor Thermo Fisher Cat# 10777019
RNAsin Plus Ribonuclease Inhibitor Promega Cat# N2611
S-Adenosyl-Methionine NEB Cat# B9003S
Sodium borohydride Sigma-Aldrich Cat# 480886
Sodium dodecyl sulfate ICN Cat# 811030
Sodium hydroxide Sigma-Aldrich Cat# S8045
Spermidine trihydrochloride Sigma-Aldrich Cat# S2501
Sucrose Fisher Scientific Cat#S/8600/60
Triethylamine VWR Cat# 84883.180
TRIS Base Melford Cat# T60040-1000.0
Triton X-100 Sigma-Aldrich Cat# X100
Tween-20 Sigma-Aldrich Cat# P1379
Uridine-13C9,15N2 50-triphosphate Sigma-Aldrich Cat# 645672-1MG
XbaI NEB Cat# R0145S
[a-32P]-GTP / 3000Ci/mmol - 10mCi/ml Perkin-Elmer Cat# BLU006H250UC
Critical Commercial Assays
Agilent SurePrint G3 Human Gene Expression
Array v3 (8x60K)
Agilent Technologies Cat# G4851C
Dual-Glo Luciferase Assay System Promega Cat# E2920
ECL Prime detection reagent kit GE Healthcare Cat# RPN2232
Fast SybrGreen PCR mastermix Applied Biosystems Cat# 4385612
High-capacity cDNA reverse transcription kit Applied Biosystems Cat# 4368814
Low Input QuickAmp Labeling Kit, One-Color Agilent Technologies Cat# 5190-2305
miRNEasy mini kit Qiagen Cat# 217004
miScript II RT kit Qiagen Cat# 218161
NEBNext SmallRNA kit NEB Cat# E7300S
Qubit dsDNA HS Assay Kit Thermo Fisher Cat# Q32851
Qubit RNA HS Assay Thermo Fisher Cat# Q32852
RNA Clean & Concentrator - 25 Zymo Cat# R1017
(Continued on next page)
Molecular Cell 74, 1–13.e1–e9, June 20, 2019 e2
Please cite this article in press as: Pandolfini et al., METTL1 Promotes let-7 MicroRNA Processing via m7G Methylation, Molecular Cell (2019), https://
doi.org/10.1016/j.molcel.2019.03.040
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
RNA Clean & Concentrator - 5 Zymo Cat# R1013
RNeasy MinElute Cleanup Kit Qiagen Cat# 74204
SuperScript III Reverse Transcriptase Thermo Fisher Cat# 18080044
Tapestation RNA ScreenTape Agilent Technologies Cat# 5067-5576
TaqMan Advanced miRNA cDNA Synthesis Kit Thermo Fisher Cat# A28007
TaqMan Fast Advanced Master Mix Applied Biosystems Cat# 4444556
TaqMan Advanced miRNA Assay (A25576) Thermo Fisher Listed in Table S8
TranscriptAid T7 High Yield Kit Thermo Fisher Cat# K0441
Universal ProbeLibrary (4683633001) Roche Listed in Table S8
Deposited Data
METTL1 Knockdown Expression Microarray data This study GEO: GSE112180
BoRed-seq and m7G-RIP-seq in A549 This study GEO: GSE112181
m7G-RIP-Seq in Caco-2 This study GEO: GSE120454
m7G-RIP-Seq in A549 METTL1 Knockdown This study GEO: GSE120455
Unprocessed imaging data This study https://data.mendeley.com/datasets/yscng45zgj/1
Experimental Models: Cell Lines
HEK-293T (Human embryonic kidney) ATCC RRID: CVCL_0063
A549 (Human lung adenocarcinoma) ATCC RRID: CVCL_0023
Caco-2 (Human colorectal adenocarcinoma) ATCC RRID: CVCL_0025
Oligonucleotides
DNA and RNA oligonucleotides are listed in
Table S8
This study N/A
GFP MISSION esiRNAs Sigma-Aldrich Cat# EHUEGFP-50UG
METTL1 MISSION esiRNAs Sigma-Aldrich Cat# EHU076851-50UG
miRIDIAN Control miRNA mimic Dharmacon Cat# CN-001000-01-05
miRIDIAN hsa-let-7e-5p miRNA mimic Dharmacon Cat# C-300479-05-0002
Recombinant DNA
Hmga2-Luc-m7 Addgene #14788
Hmga2-Luc-wt Addgene #14785
PAX2 Addgene #12260
pcDNA3-pri-let-7e Addgene #51380
pcDNA4/TO/cmycDrosha Addgene #10828
pHIV-ZsGreen Addgene #18121
pLKO-TETon-Puro Addgene #21915
pMD2.G Addgene #12259
pMirGlo Promega Cat# E1330
Software and Algorithms
Bioconductor https://www.bioconductor.org/ N/A
DESeq2 Love et al., 2014 N/A
FastQC https://github.com/s-andrews/
FastQC
N/A
featureCounts Liao et al., 2014 N/A
G4Hunter Bedrat et al., 2016 N/A
Gage Luo et al., 2009 N/A
gbm Freund and Schapire, 1997 N/A
limma Smyth et al., 2005 N/A
miRWalk 2.0 Dweep and Gretz, 2015 N/A
Pathwiew Luo et al. 2017 N/A
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Quadparser Huppert and Balasubramanian,
2005
N/A
R statistical environment https://www.r-project.org/ N/A
RNAfold Lorenz et al. 2011 N/A
STAR Dobin et al., 2013 N/A
Sylamer van Dongen et al., 2008 N/A
Trimmomatic Bolger et al., 2014 N/A
Feature Extraction Software Agilent Technologies G4463AA
XCalibur Thermo Fisher OPTON-30487
Other
ACQUITY UPLC HSS T3 Column Waters Corp Cat# 186005614
Amicon 30kDa MWCO spin-column Merck Millipore Cat# Z717185
Amersham Hybond-C Extra Nitrocellulose
membrane
GE Healthcare Cat# RPN203D
Amersham Hybond-N+ Nylon Membrane GE Healthcare Cat# RPN2020B
Amersham Hyperfilm HS autoradiography film GE Healthcare Cat# 28906836
Bradford assay Bio-Rad Cat# 5000006
Denhart’s solution Thermo Fisher Cat# 750018
Dulbecco’s Modified Essential Medium Gibco Cat# 41965-039
Dynabeads MyOne Streptavidin C1 Thermo Fisher Cat# 65001
Dynabeads Protein G Thermo Fisher Cat# 10004D
Eagle’s Modified Essential Medium Sigma-Aldrich Cat# M2279
Fetal Bovine Serum Gibco Cat# 10270-106
Illustra MicroSpin G-25 spin column GE Healthcare Cat# 27532501
Migration assay transwell inserts (8 mm) Corning Cat# 3422
Novex TBE 6% precast gel Thermo Fisher Cat# EC6265BOX
Novex TBE-Urea 10% precast gel Thermo Fisher Cat# EC6875BOX
Novex TBE-Urea 15% precast gel Thermo Fisher Cat# EC6885BOX
Novex TBE-Urea 6% precast gel Thermo Fisher Cat# EC6865BOX
Novex TBE-Urea Sample Buffer Thermo Fisher Cat# LC6876
Penicillin/Streptomycin/Glutamine Gibco Cat# 10378016
Protein G Sepharose 4 Fast Flow beads GE Healthcare Cat# 17-0618-01
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Queries and reagent requests may be directed and will be fulfilled by the lead contact, Tony Kouzarides (tony.kouzarides@gurdon.
cam.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
HEK293T (RRID:CVCL_0063) and A549 cells (RRID:CVCL_0023) were cultured in DMEM (Invitrogen), supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin/glutamine (PSQ). Caco-2 cells (RRID:CVCL_0025) were cultured in Eagle’s
Minimum Essential Medium, supplemented with 20%FBS and 1%PSQ. Cell lines were obtained from the ATCC and tested negative
for mycoplasma contamination. Human cell lines used are not listed in the cross-contaminated or misidentified cell lines database
curated by the International Cell Line Authentication Committee (ICLAC).
Lentiviral vector preparation and cell transduction
For virus production, HEK293T cells were transfected with the lentiviral vector pLKO-TETon-Puro for METTL1 knockdown, or
Zs-Green-HIV for METTL1 rescue experiments, together with the packaging plasmids PAX2 (Addgene Plasmid #12260) and
pMD2.G (Addgene Plasmid #12259) at a 1:1.5:0.5 ratio using Lipofectamine 2000 reagent (Invitrogen) according to theMolecular Cell 74, 1–13.e1–e9, June 20, 2019 e4
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doi.org/10.1016/j.molcel.2019.03.040manufacturer’s instructions. Supernatants were harvested 48 h and 72 h after transfection. Cells (5 3 105) were mixed in 2 ml viral
supernatant supplemented with 8 mg/ml polybrene (Millipore), followed by spinfection (60 min, 900 g, 25C) and further incubated
overnight at 37C. For METTL1 knockdown experiments, cells were replated in fresh medium containing 1 mg/ml puromycin and
kept in selection medium for 7 days. For METTL1 rescue experiments, GFP+ cells were isolated using a SONY SH800 cell sorter
48 h after infection.
Generation of conditional knockdown cells
A549 or Caco-2 cells were infected with pLKO-TETon-Puro lentiviral vectors (Addgene Plasmid #21915) expressing shRNAs against
the coding sequence of human METTL1 or a scrambled control as described above. The shRNA sequences are listed in Table S8.
shRNA was induced by treatment with 200 ng/ml doxycycline for the indicated times.
METHOD DETAILS
BoRed-Seq and m7G-RIP-Seq
The detailed protocol of all the procedures required to performBoRed-Seq andm7GRNA immunoprecipitation experiments on small
RNAs is described in Methods S1. Single-end 50-bp stranded smallRNA libraries were prepared using the NEBNext SmallRNA kit
(NEB) according to the manufacturer’s recommendations and sequenced on a HiSeq 4000 (Illumina).
RNA immunoblots and dot blots
RNAwas resolved by denaturing polyacrylamide gel electrophoresis using Novex TBE-urea 15%precast gels (Thermo Fisher). Equal
loading was checked by staining with ethidium bromide (Sigma-Aldrich), then RNAwas transferred to a nylonmembrane (Amersham
Hybond-N+, GE Healthcare) by wet electro-blotting in TBE (45 min at 400 mA).
For dot-blot analysis, input RNA or RNA immunoprecipitated with either anti-m7G or isotypic non-specific antibodies was spotted
onto a nitrocellulose membrane and UV cross-linked at 254 nm (120 mJ/cm2). The membranes were blocked in Denhart’s solution
(1% Ficoll, 1% polyvinylpyrrolidone, 1% bovine serum albumin; Thermo Fisher) for 1 h at room temperature and incubated with m7G
antibody for 1 h at room temperature. Signal was detected using HRP conjugated secondary antibodies and ECL (GE Healthcare)
and developed on a Chemidoc MP machine (BioRad).
Global gene expression profiling
Cells were lysed in Qiazol (QIAGEN) and total RNA was extracted with miRNeasy mini kit (QIAGEN). RNA quality was assessed using
an Agilent Tapestation RNA; 50 ng of RNA were labeled with Low Input QuickAmp Labeling Kit, One-Color (Agilent Technologies),
purified and hybridized overnight onto an Agilent SurePrint G3 Human Gene Expression Array v3 (8x60K) before detection according
to the manufacturer’s instructions. An Agilent DNA microarray scanner (model G2505C) was used for slide acquisition.
RT-qPCR
Cells were lysed in Qiazol (QIAGEN) and total RNA was purified using the miRNEasy mini kit (QIAGEN) according to the
manufacturer’s instructions. For mRNA detection, 1 mg of purified total RNA was reverse transcribed using the high-capacity
cDNA reverse transcription kit (Applied Biosystems). To quantify gene expression, we used probes from Universal ProbeLibrary
(UPL; Roche) with TaqMan Fast Advanced Master Mix (Thermo Fisher).
For specific pri- and pre-miRNA quantification, we size-fractionated large (> 200nt, containing the pri-miRNAs) and small RNAs
(< 200nt, containing pre-miRNAs) using RNA Clean & Concentrator 5 column kits (Zymo), as per the manufacturer’s instructions.
Pri-miRNAs were reverse transcribed using the High-Capacity cDNA reverse transcription kit (Applied Biosystems), which employs
random nonamer priming and favors longmolecules. Pre-miRNAs were reverse transcribed with miScript II RT kit (QIAGEN), which is
more efficient on short RNAs. Primers were designed to anneal either within the stem loop (pre-miRNAs) or to overlap the DROSHA
cleavage sites (pri-miRNAs). Both pri- and pre-miRNAs were quantified using Fast SybrGreen PCR mastermix (Applied Biosystems)
according to the manufacturer’s instructions.
For mature miRNA detection, total RNA was reverse transcribed and amplified using the Taqman AdvancedmiRNA cDNA Synthe-
sis Kit from Thermo Fisher Scientific. The levels of specific miRNAs were measured with Taqman advanced miRNA Assays from
Thermo Fisher Scientific. All the RT-qPCR experiments were run on an ABI 7900 real-time PCR machine (Applied Biosystems).
GAPDH and RNY1 were used as housekeeping genes for RT-qPCR normalization of long and small RNAs, respectively. Primer
sequences, UPL probe numbers and assay IDs are listed in Table S8.
Western blotting
For total cell protein extraction and western blot analysis, cells were lysed in a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1% Triton X-100, 0.5% deoxycholic acid, 0.1% sodium dodecyl sulfate, Complete protease inhibitor cocktail (Roche) and
cleared by centrifugation. The protein concentration was determined by Bradford assay (Bio-Rad). Proteins were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Hybond-C Extra, GE Healthcare).
Membranes were blocked with 5%milk proteins in TBST (50 mM Tris-HCl pH 7.6, 150mMNaCl, 0.05% Tween-20), and probed withe5 Molecular Cell 74, 1–13.e1–e9, June 20, 2019
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doi.org/10.1016/j.molcel.2019.03.040primary antibodies overnight. Membraneswere thenwashed three timeswith TBST (15min each) and probedwith aHRP-conjugated
secondary anti-rabbit antibody for 1 h. After three more washes, signal was detected using HRP conjugated secondary antibodies
and ECL (GE Healthcare) and developed on a BioRad Chemidoc MP machine.
Migration assays
For transwell migration assays, the lower surface of the transwell inserts (8 mm; Corning) was coated with human recombinant
fibronectin (1 mg/ml, 1 h at RT; Sigma-Aldrich). A549 cells were serum-starved overnight and seeded (33 104) in serum-free medium
on transwell inserts. After 7 h incubation in wells containing DMEM+20% FBS, inserts were stained with crystal violet and cells on
the lower surface were counted (blindly).
Proliferation assays
4 days after shRNA induction, 105 A549 METTL1 knockdown or Ctrl cells were plated in each well of 6-well cell culture plates in
normal culture medium. Cells were counted daily for the following three days using a Countess II cell counter (Thermo Fisher).
Mature miRNA/hairpin transfection
20 pmol of hsa-let-7e-5pmiRNA mimic or control miRNAs (miRIDIAN, Dharmacon) were transfected into 2.53 105 A549 cells using
2 mL of Lipofectamine 2000 (Thermo Fisher). 10 pmol of pri-let-7e hairpins (Integrated DNA Technologies) were transfected into
1.5 3 105 A549 cells using the same amount of Lipofectamine as above.
Luciferase assay
A dual luciferase reporter harboring the 30-UTR of mouse Hmga2 was generated extracting the XbaI-NotI digestion fragments from
either Hmga2-Luc-wt or Hmga2-Luc-m7 (Mayr et al., 2007; Addgene plasmids #14785 and #14788) and subcloning them into
pMirGlo (Promega). In order to generate stable reporter lines, A549 cells were transfected with the pMirGlo-hmga2(30-UTR) con-
structs. 24 h after transfection, cells were selected using 300 mg/ml G418 for 7 days. Subsequently, cells were transfected with
20 pmol of MISSION esiRNAs (Sigma-Aldrich) against human METTL1 or GFP. 24 h after transfection, Firefly and Renilla luciferase
activities were measured using the Dual-Luciferase Reporter Assay System (Promega) on a CLARIOstar microplate reader (BMG
Labtech).
METTL1 rescue experiments
cDNA was obtained by reverse transcription of A549 RNA with Superscript III (Thermo Fisher), then the METTL1 full-length coding
sequence was amplified by PCR and cloned into pHIV-ZsGreen plasmid (Addgene plasmid #18121) using restriction sites XbaI and
NotI. In order to generate an shRNA-resistant METTL1 sequence, synonymous substitutions were introduced in the codons
corresponding to shRNA binding sites by long DNA fragment synthesis (GeneArt Strings; Thermo Fisher) of the N-terminal portion
of METTL1 (up to NheI site). The in vitro synthesized fragment was swapped into pHIV-ZsGreen-METTL1 using restriction sites
NotI and NheI. The same approach was combined to codon mutagenesis to generate the catalytically inactive METTL1 variant
EIR/AAA (amino acids 107-109, that form the SAM-binding pocket of the enzyme; see Figure S2I). Primer and long oligonucleotide
sequences are listed in Table S8.
METTL1 UV-CLIP
Adherent cells in a 15 cm dish were rinsed twice in ice-cold PBS, cross-linked at 254 nm (120 mJ/cm2), scraped and lysed on ice for
10 min in 1 mL of fresh lysis buffer (25 mM Tris-HCl pH 8.0, 150 mMNaCl, 2 mMMgCl2, 0.5% NP-40, 5 mMDTT) supplemented with
protease inhibitors (Complete tablets, Roche) and RNase inhibitors (RNaseOUT; Thermo Fisher). Lysates were vortexed, then
centrifuged at max speed at 4C for 5 min. The supernatants were used in immunoprecipitation (IP) assay with 5 mg of anti
METTL1-antibody (sheep polyclonal obtained by MRC Protein Phosphorylation Unit, #588192; Cartlidge et al., 2005) or control iso-
typic IgG at 4C for 90min, with rotation. 80 mL of ProteinGDynabeads (Invitrogen) per IP reactionwere rinsed 2 timeswith lysis buffer
and blocked with 1 mg/ml BSA (NEB) for 2 h at 4C. Beads were resuspended in 100 mL lysis buffer, then added to the IP tube. The
reaction was incubated at 4C for 2 h with rotation. Beads were then washed twice with high-salt buffer (25 mM Tris-HCl pH 8.0,
500 mM NaCl, 1 mM MgCl2, 1% NP-40, 5 mM DTT) and three times with lysis buffer. Immunoprecipitated samples were treated
with DNase I (QIAGEN) followed by digestion with Proteinase K (NEB). RNA was purified using an RNeasy MinElute column kit
(QIAGEN).
Expression and purification of recombinant METTL1/WDR4 (Evotec)
The constructs EV4866 (his-METTL1) and EV4868 (flag-WDR4) were cloned into plasmid pTriIJ-HV (Evotec). Recombinant virus was
produced by co-transfecting transfer plasmid DNA and bacmid DNA in insect cells. 100 ng bacmid DNA and 500 ng transfer plasmid
DNA were mixed with 2 ml Cellfectin II transfection reagent (Invitrogen) in 200 ml TC100 media (Sigma) and incubated at room
temperature for 2-3 h. Sf21 insect cells, grown to 80%–90% confluency in 24 well plates were washed with TC100 before adding
0.2 mL TC100 and 0.2 mL co-transfection mix. After overnight incubation, 0.6 mL Sf900 II SFMmedia containing 5 mg/ml gentamicin
was added and the cells were incubated at 27C for six days with humidity. The cells were observed under an inverted microscopeMolecular Cell 74, 1–13.e1–e9, June 20, 2019 e6
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observed within 1 h. Following confirmation of successful transfection, the medium containing the recombinant virus (P0) was
harvested into a sterile deep well block and stored in the dark at 4C. P1 BIICs (baculovirus-infected insect cells) were amplified
in a sterile 24-deep well block by infecting Sf21 cells grown in Sf900 II SFM media containing 5 mg/ml gentamicin with P0 virus.
The infected cultures were incubated for 72-120 h at 27C with shaking at 360 rpm. P1-BIICs were harvested by centrifugation of
the block and virus supernatant was removed to a fresh block and stored at 4C. The cells were then re-suspended in freezing
mix (Sf900 II + 10% heat inactivated FBS + 10% DMSO) and frozen gradually to 80C, in the block. Working P2-BIICs were ampli-
fied by infecting Sf21 cells grown in shake flasks at MOI-0.1 using P1-BIICs and incubated for 72 h. P2-BIICs were harvested by
centrifugation and infected cells were resuspended in freezing media and stored at 80C. Sf21 cells grown in Sf900 II SFM media
plus 5 mg/ml gentamicin were infected with both EV4866 and EV4868 P2 BIICs at an MOI of 2 (1+1). The infected culture was incu-
bated for 72 h at 27Cwith shaking at 110 rpm, before harvesting by centrifugation and storing at80C. Thawed cells were lysed in
25 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM TCEP, 5% glycerol, 0.25% CHAPS supplemented with Complete EDTA-free protease
inhibitor tablets (Roche). Samples were homogenized for 20-30 s with an IKA Ultra-Turrax and sonicated in a Branson probe
sonicator (cycles of 30 s on, 30 s off for 5 min at 40% amplitude). Samples were centrifuged at 45000 rpm for 50 min to remove
insoluble material. Purification was carried out by sequential Ni-affinity and size-exclusion chromatography on an A¨KTA Xpress
system (GE). Samples were bound to 1 mL HisTrap FF column, washed with 25 mM Tris-HCl pH 8.0, 300 mM NaCl, 1mM TCEP,
5% glycerol, 20 mM imidazole and eluted with a step elution over 20 CV of 25 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM TCEP,
5% glycerol and 500 mM imidazole at a flow rate of 0.8 ml/min. This was followed by size-exclusion on a 16/60 S200 column
(25 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM TCEP, 5% glycerol) at a flow rate of 1 ml/min. Purified protein was analyzed by
SDS-PAGE, western blotting and measurement of A260/A280 to estimate levels of contaminating nucleosides. Aliquoted protein
was snap-frozen in liquid nitrogen and stored at 80C.
In vitro RNA methylation assays
Recombinant METTL1/WDR4 (300 nM; Evotec) was incubated for 2 h with S-adenosylmethionine (15 mM) and oligonucleotide (1 mM)
in a Tris-HCl pH 8.0 buffer (20 mM) supplemented with 1 mM DTT and 0.01% Triton X-100.
Mass spectrometry analysis of RNA nucleoside m7G modification
Nucleosides were prepared from enzyme-processed RNA by enzymatic digestion, using a cocktail of Benzonase (Merck), Phospho-
diesterase 1 (Merck), and Antarctic Phosphatase (New England Biolabs) as described previously (van Delft et al., 2017). The reactions
were filtered using an Amicon 30kDa MWCO spin-column (Merck) to remove protein and the filtrate was mixed with a 2x loading
buffer containing 0.1% formic acid and an internal standard (13C-labeled uridine generated from 645672-1MG Merck KGaA, previ-
ously treatedwith Antarctic Phosphatase). The sampleswere loaded onto an ACQUITYUPLCHSST3Column, 100 A˚, 1.8 mm, 1mmX
100 mm (Waters Corp., Milford, MA, USA) and resolved using a gradient of 2%–10% acetonitrile in 0.1% formic acid over 10 min.
Mass spectrometric analysis was performed in positive ion mode on an Orbitrap QExactive HF (Thermo Fisher, Waltham, MA,
USA) mass spectrometer. Standard dilutions of all experimental nucleosides were prepared and analyzed in parallel. There were
three technical replicates of each sample and the analytical processing was performed using XCalibur Software (Thermo Fisher).
Mature miRNA isolation
Mature miRNA fraction was isolated from total RNA by gel extraction: RNA was denatured by incubation at 73C for 3 min in 2X Urea
Sample Buffer (Thermo Fisher) and run in a 10% TBE–urea precast polyacrylamide gel (Thermo Fisher) at 250V for 12 min. Gel was
visualized by ethidium bromide staining and the region corresponding to the expected size of mature miRNAs was excised using a
synthetic 20-nt RNA ruler. After breaking the gel, miRNAswere eluted in a sodium acetate buffer (0.3M sodium acetate, pH 5.2, 5mM
EDTA, 0.1% sodium dodecylsulfate) by freeze-thawing once on dry ice and incubating at 4C overnight. miRNAs were purified by
ethanol precipitation.
Context-specific mass spectrometry analysis of miRNA m7G modification
Oligonucleotides were prepared frommiRNA fraction using RNase A (Thermo Fisher) and chromatographically separated by ion pair
reverse phase chromatography (200mMHexafluoroisopropanol [HFIP], 8.5mM triethylamine [TEA] in water as eluent A, and 100mM
HFIP, 4.25 mM TEA in methanol as eluent B). The oligonucleotides were resolved by a gradient of 2.5% to 20% B at 200 nl/min on
Acclaim PepMapC18 solid phase (Thermo Fisher) and characterized by negative ion tandemLC-MS in a hybrid quadrupole – orbitrap
(QExactive HF, Thermo Fisher). Data were collected in data-dependent acquisition mode in pathfinding experiments before
subsequent hybrid acquisition investigation. Full scan MS1 data were acquired between 700 and 3500 m/z and extracted ion chro-
matograms from these data were used for label-free quantification of oligonucleotides derived from let-7. MS2 data were collected
in subsequent scan events for the same let-7 oligonucleotides by targeted, multiplexed, data-independent acquisition on filtered
precursor ion masses multiplexed from the double and triple charge states of unmodified and monomethylated AGGAGGU
(m/z of 1180.158, 786.436, 1187.166 and 791.108, with a window of 3 m/z). Technical replicates of n = 3 were acquired, with
MS2 ions matched with to within 5 ppm.e7 Molecular Cell 74, 1–13.e1–e9, June 20, 2019
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Plasmid pcDNA3-pri-let-7e (Addgene #51380; Heo et al., 2008) linearized by digestion with XbaI (NEB) was used as a template for
RNA in vitro transcription in the presence of [a-32P]-GTP (Perkin Elmer) using TranscriptAid T7 High Yield Kit (Thermo Fisher). The
resulting RNA (369bp) was denatured by incubation at 73C for 3 min in 2X Urea Sample Buffer (Thermo Fisher) and run in a 6%
TBE–urea precast polyacrylamide gel (Thermo Fisher). The band corresponding to the expected size of pri-let-7e transcript was
excised using autoradiography and, after breaking the gel, RNA was eluted as described above for mature miRNA isolation.
2.5 mg of 32P-labeled pri-let-7e (1 mM) were incubated for 3 h at 37C in the presence of recombinant METTL1/WDR4 (300 nM)
and S-adenosylmethionine (1 mM) in a methylation buffer (85 mM Tris-HCl pH 8.0, 1.4 mM DTT, 0.07 mM EDTA, 1 mM spermidine).
Methylated pri-let-7e was isolated by immunoprecipitation using m7G-specific antibody, purified on RNA Clean & Concentrator - 5
columns (Zymo) and quantified by scintillation counting (Hidex 300 SL).
Isolation of DROSHA by IP
Immunopurification of DROSHA and in vitro processing assays were performed according to a published protocol (Lee et al., 2002).
HEK293T cells transfected with pcDNA4/TO/cmycDrosha plasmid (Landthaler et al., 2004; Addgene plasmid #10828) were lysed
after 48 h in buffer D (20 mM HEPES–KOH pH 7.9, 100 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 5% glycerol) by
sonication (Bioruptor: 5 min; 30 s ON / 30 s OFF, 200W) followed by centrifugation. 2 mg of crude extract were incubated with
12 mg of anti-myc-tag antibody (Abcam) for 2 h at 4C, then the recombinant enzyme was pulled-down with 30 mL Protein G Sephar-
ose 4 Fast Flow beads (GE Healthcare) and washed 4 times in buffer D. Whole-cell extracts were prepared from control andMETTL1
knockdown A549 cells using the same lysis protocol as above.
In vitro miRNA Processing Assays
For comparing the pri- to pre-miRNA processing efficiency by DROSHA, 30000 cpm (50-100 ng) of either naive or in vitromethylated
pri-let-7e were incubated with 15 mL of DROSHA-IP beads, 6.4 mMMgCl2 and 1U/ml RNaseOUT RNase inhibitor (ThermoFisher) for
80 min at 37C.
For evaluating the processing activity of METTL1 depleted cells, 10 mL of processing reaction containing 5 mL of whole-cell extract,
1 mL of solution A (32mMMgCl2, 5mMATP, 200mMcreatine phosphate), 1 mL 32mMS-adenosyl methionine, 1 U/ml RNase inhibitor
(Thermo Fisher) and the labeled transcripts (104-105 c.p.m.) were incubated at 37C for 120 min.
All processing reactions were purified with RNA Clean & Concentrator - 5 column kit (Zymo), measured and equalized by scintil-
lation counting, resolved on a 6%TBE–urea precast polyacrylamide gel (Thermo Fisher) and developed by autoradiography exposing
the dried gel on Amersham Hyperfilm high-sensitivity film (GE Healthcare).
Circular dichroism spectroscopy
CD experiments were conducted on a Chirascan Plus spectropolarimeter. Oligonucleotide solutions were prepared at a final con-
centration of 10 mM (rG4-let-7e oligonucleotides) or 2.5 mM (let-7e hairpins) in 10 mM lithium cacodylate (pH 7.2) containing 1mM
EDTA and supplemented with 100 mM of LiCl, NaCl or KCl. Oligonucleotides were annealed by heating at 95C for 3 min and cooling
the solutions at 4C for 4 h. Scans were performed over the range of 200–320 nm at 5C. Each trace was the result of the average of
three scans taken with a step size of 1 nm, a time per point of 1 s and a bandwidth of 1 nm. A blank sample containing only buffer was
treated in the samemanner and subtracted from the collected data. The data were finally baseline corrected at 320 nm. Denaturation
experiments were performed by heating the samples to 95Cusing the stepped temperature rampingmode, a setting time of 10 s and
with data collection every 1C monitoring the CD signal at 263 and 210 nm. Differential melting curves (quantification of folded
fractions) were obtained by subtracting the upper baseline to the signal and dividing by the difference between the upper and lower
baseline. Melting temperatures (T1/2) values were extracted as the local minima of the first derivatives of a Boltzman or bi-phasic
dose-response fittings of the differential curves.
Polysome fractionation
Control orMETTL1 knockdown cells (n = 2) were treated 5 days after doxycycline induction with 0.1mg/ml cycloheximide for 5min at
37C, then they were lysed and polysomes were fractionated on a sucrose gradient while measuring absorbance at 254 nm (Panda
et al., 2017).
QUANTIFICATION AND STATISTICAL ANALYSIS
Bioinformatic analysis of smallRNA sequencing
Multiplexed reads were split on the basis of their barcodes using Illumina Basespace. Read quality was assessed using
FastQC program (https://github.com/s-andrews/FastQC). Library adaptors were trimmed with Trimmomatic (Bolger et al., 2014),
and reads were mapped to the human genome (NCBI GRCh38/hg38) with STAR (Dobin et al., 2013), using the parameters
of ENCODE guidelines: --runThreadN 15 --sjdbGTFfile /path/to/GENCODE_miRNA_subset.gtf --alignEndsType EndToEnd
--outFilterMismatchNmax 1 --outFilterMultimapScoreRange 0 --outSAMtype BAM SortedByCoordinate --outFilterMultimapNmax
10 --outSAMunmapped Within --outFilterScoreMinOverLread 0 --outFilterMatchNminOverLread 0 --outFilterMatchNminMolecular Cell 74, 1–13.e1–e9, June 20, 2019 e8
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doi.org/10.1016/j.molcel.2019.03.04016 --alignSJDBoverhangMin 1000 --alignIntronMax 1 (Davis et al., 2018). Reads were summarized using featureCounts (Liao et al.,
2014) according tomiRbase22 annotation (Kozomara andGriffiths-Jones, 2014) of maturemiRNAs. Differential miRNA enrichment in
either m7G-RIP or BoRed-Pulldown over input/control sample was evaluated through negative binomial Wald test with the R pack-
age DESeq2 (Love et al., 2014; n = 2 for BoRed-Seq; n = 5 for m7G-RIP-Seq experiments).
Global gene expression analysis
Microarray spot analysis was performed with Feature Extraction software (Agilent Technologies). Data were background-corrected
and quantile normalized among arrays using the Bioconductor package limma (Smyth and Speed, 2003; Smyth et al., 2005). The
statistical significance of differential gene expression was calculated with the empirical Bayes method implemented in limma.
KEGG pathway ontologies over-represented in the subset of genes upregulated or downregulated upon METTL1 knockdown
were evaluated using the R package Gage (Luo et al., 2009, 2017).
In order to identify themRNAs that are predicted to be targets of selectedmiRNAs, we extracted the positive hits of at least 3 out of
6 in silico prediction algorithms (namely miRWalk, miRanda, miRDB, Pictar2, RNA22 and Targetscan) using miRWalk 2.0 web server
(Dweep and Gretz, 2015).
For unbiased analysis of miRNA seed sequences enriched in the top upregulated genes upon METTL1 knockdown, we took
advantage of the Sylamer online software (van Dongen et al., 2008).
To produce a classification model predicting mRNA upregulation upon METTL1 knockdown, we extracted the subset of genes
expressed above the background (log2 Average expression > 6). Genes displaying a log2FoldChange > 1 and a FDR < 0.05 were
considered upregulated, and then a model employing the presence of putative miRNA target sites as predictors was generated
by gradient boosting using R package gbm (Freund and Schapire, 1997).
Bioinformatic prediction of G-quadruplexes
Stem-loop and mature miRNA sequences were recovered from miRBase (Kozomara and Griffiths-Jones, 2014) release 22. These
sequences were used to calculate the quantitative parameters used to describe the different miRNA features discussed in this
manuscript. Base composition was assessed using a custom Python script. G-score, a quantitative estimation of G-richness and
G-skewness, is based on the G4Hunter algorithm (Bedrat et al., 2016). Briefly, each position in a sequence is given a score between
4 and 4. To account for G-richness, a single G is given a score of 1, in a GG sequence each G is given a score of 2; in a GGG
sequence each G is given a score of 3; and in a sequence of 4 or more Gs each G is given a score of 4. To account for G-skewness,
Cs are scored similarly but their values are negative. The Gscore is the maximum value obtained while scanning miRNA sequences
using a 20nt window and averaging the score of each nucleotide over the considered window.
G-quadruplex forming motifs, G2N7, G2N3, G3N7 and G3N12 are sequences of the form G2+N1–7G2+N1–7G2+N1–7G2+, G2+N1–
3G2+N1–3G2+N1–3G2+, G3+N1–7G3+N1–7G3+N1–7G3+ and G3+N1–12G3+N1–12G3+N1–12G3+ respectively, where N is any base. G3N7
represents the strict definition of G4 forming sequences according to the Quadparser algorithm (Huppert and Balasubramanian,
2005). Other motifs represent the loose definition of G4 forming sequences (Kwok et al., 2016a). The presence of each motif within
miRNA sequences was assessed using the re.finditer function in custom python scripts.
RNA secondary structures were predicted using the RNAfold 2.2.10 algorithm of the ViennaRNA package (Lorenz et al., 2011).
RNAfold computes the minimum free energy (MFE) of optimal secondary structures via estimation of base pairing probabilities.
MFEs of dsRNA secondary structures (DG0dsRNA) were computed at 37
C.MFEs of G4 secondary structures (DG0G4) were computed
by subtracting MFEs obtained when considering G4 formation into the structure prediction algorithm to the previous values (DG0G4 =
DG0dsRNA - DG
0
(dsRNA + G4)). RNAfold was used to assess the stability of predicted RNA structures within miRNA sequences using a
20nt slidingwindow.m7G-containingmiRNAs are the subset of miRNAs that have been enriched from the total population of miRNAs
using both the BoRed-Seq and m7G-RIP-Seq protocols. Background is the rest of annotated miRNAs. For assessing the local
enrichment of structures within m7G-containing precursor miRNAs, pre-miRNA sequences were piled up and centered, MFE values
were then averaged at each position. Data were compiled and plotted using R.
Statistical analysis
All general statistical analyses were performed using either a two-tailed Student’s t test or a Wilcoxon test (when distributions were
assessed not to be normal and homoscedastic) at a confidence interval of 95%, unless otherwise specified. No statistical methods
were used to predetermine sample size.
DATA AND SOFTWARE AVAILABILITY
Data Resource
Raw genomic data have been deposited in the Gene Expression Omnibus database with accession number GSE112182 (Expression
Microarray data: GSE112180; BoRed-seq and m7G-RIP-seq in A549: GSE112181; m7G-RIP-Seq in Caco-2: GSE120454; m7G-RIP-
Seq in A549METTL1 knockdown: GSE120455). Unprocessed imaging data are deposited onMendeley Data: (https://data.mendeley.
com/datasets/yscng45zgj/1). All other data and analysis scripts are available from the corresponding author upon reasonable request.e9 Molecular Cell 74, 1–13.e1–e9, June 20, 2019
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Figure S1
Figure S1 | High-throughput profiling of m7G modification in miRNAs. Related to Figure 1. 
A, Schematic  representation  (top)  of  the  expected  cleavage  of  18S rRNA  after  NaBH4  +  aniline  treatment  and
electropherogram analysis (bottom) of untreated and treated total RNA from A549 cells.  B, Immunoprecipitation with anti-
m7G  antibody  does  not  enrich  RNAs  containing  five  different  guanine  modifications  (including  four  methylations)  as
determined by mass spectroscopy. Error bars represent S.E.M. C, HPLC trace of the four canonical RNA nucleosides along
with  7-methylguanosine,  showing  retention  times  that  are  an  exact  match  with  pure  nucleosides  run  as  quantitation
standards. D, Extracted ion chromatogram of 7-methylguanosine, with the accompanying mass spectra showing the intact
protonated  precursor  ion of  the nucleoside [M+H]  (middle  panel)  and the 7-methylguanine  ion generated  by in-source
fragmentation as an internal verification of its identity.
Figure S2
Figure S2 | Validation of BoRed-Seq and m7G-RIP-Seq. Related to Figure 1. 
A, Electropherogram analyses of total RNA before and after immunoprecipitation with an m7G-specific antibody showing
specific enrichment for 18S rRNA in the immunoprecipitate. B, Read counts for tRNAs from the BoRed-Seq and m7G-RIP-
Seq experiments are shown.  Error bars represent S.E.M. C,  Venn diagram showing the high overlap between miRNAs
significantly enriched in either m7G-RIP-Seq or BoRed-Seq of A549 cells, respectively. Confidence interval of the odds ratio
(OR) and P-value, as obtained by Fisher’s exact test, are indicated in the table below.  D, Read counts for the indicated
miRNA from the BoRed-Seq and RIP-Seq experiments are shown. Error bars represent S.E.M. E, Scatter plot showing the
absence of correlation between m7G and miRNA expression levels. Labels show the m7G containing miRNAs amongst the
top 20 most expressed ones and their absolute ranking.  F,  Scatter plot  of  m7G-RIP-Seq miRNA enrichment in Caco-2
versus  A549  cells,  highlighting  a  high  degree  of  correlation,  as  indicated  by  R2  Pearson  correlation  coefficient.  G,
Immunoblot using an m7G-specific antibody shows a reduction of m7G levels in tRNAs upon  METTL1 knockdown. Right
graph  shows  the  average  ±  S.E.M. digital  quantification  of  the  m7G signal  (*P<0.05,  two  tailed  t-test).  H, RT-qPCR
quantification  of  let-7e-5p, miR-125a-5p and  miR-148a-3p upon  METTL1 KD  in  Caco-2  cells.  The  average  of  four
independent biological replicates ± S.D. is shown (**P<0.01, two tailed t-test). I, Crystal structure of METTL1 in complex with
S-adenosylmethionine (PDB file: 3CKK). The EIR (107-109) amino acids mutated to alanine to generate the catalytically
inactive mutant are shown in red. J, RNA immunoblot with an m7G-specific antibody on total RNA from METTL1 knockdown
or control  cells over-expressing either  WT METTL1 or a catalytically inactive METTL1 (c.i.).  K, Polysome fractionation
analysis. Cell extracts from control or METTL1 knockdown cells were prepared and resolved in a 5–50% sucrose gradient.
The absorbance at 254 nm was continuously measured. The peaks corresponding to free 40S and 60S subunits, 80S and
polysomes are indicated. Shaded area in grey indicates the S.E.M. of two independent samples for each condition.
Figure S3
Figure S3 | Effects of targeting METTL1 in A549 cells. Related to Figure 2. 
A, migration assay of A549 cells.  Increased migration due to METTL1 KD is rescued by the expression of WT METTL1 (+),
but  not  by  a  catalytically  inactive  version  of  the  enzyme (c.i.).  B,C,D,E,  Graphical  representation  of  KEGG  pathway
regulation,  showing  up-regulation  of  ECM-receptor  interaction (B),  adherens  junction (C),  axon guidance (D)  and focal
adhesion (E).  Data  were  obtained by comparing  RNA expression data  from  METTL1  KD and control  A549 cells  (up-
regulated genes, red; down-regulated genes, green). F, Sylamer miRNA target seed motif analysis on up-regulated mRNAs
upon METTL1 KD, showing a specific enrichment for the let-7 (5p) seed motif. G, representative cell migration genes whose
expression is upregulated upon METTL1 KD, which are targets of let-7e-5p, miR-125a-5p or both (for all of them FDR<0.05,
as evaluated with limma). H, A gradient boosting classifier was used to model the mRNA expression fold changes observed
by microarray analysis as a function of the presence of seed sites for different miRNAs in 3'-UTRs. Receiver operating
characteristic (ROC) curve displays the goodness of the model, with an area under ROC (AUC) of 0.68. The presence of let-
7 (5p) seed sequence within an mRNA represents the strongest predictive factor for its up-regulation upon METTL1 KD, as
shown by the top 20 predictor list. The marginal effect plot shows that there is a positive correlation between the number of
seeds in the 3'-UTR and mRNA up-regulation.
Figure S4
Figure S4 | miRNA processing is dependent on m7G. Related to Figure 3 and 4. 
A, HMGA2 expression measured by RT-qPCR in Caco-2 cells infected with METTL1-specific or control (Scr) TET-inducible
shRNAs five days after doxycycline treatment. The average of five biological replicates ± S.D. is shown (***p<0.001, two
tailed t-test). B, Western blot showing METTL1, HMGA2 and β-tubulin protein levels in Caco-2 cells infected with METTL1-
specific or control (Scramble) TET-inducible shRNAs five days after doxycycline treatment. Two representative biological
replicates of a total of four are shown. C, BoRed and m7G-RIP coupled to RT-qPCR of HMGA2 in A549 cells. 18S rRNA is
used as a positive control; GAPDH is a negative control. let-7e-5p levels are replotted alongside as a positive reference. The
average of three biological and technical replicates ± S.E.M. are shown. D, Western blot showing METTL1 down-regulation
upon transfection with  METTL1 specific siRNAs in A549 cells stably expressing a luciferase cDNA with a  Hmga2-3'-UTR
with mutated let-7 seed sites. Two independent transfections of a total of four replicates are shown. E, CLIP-qPCR using a
METTL1-specific antibody or a non-specific IgG. The levels of immunoprecipitated miR-148a primary hairpin are shown. The
average of two independent immunoprecipitation reactions ± S.E.M. is presented (*P<0.05, two tailed t-test).  F, RT-qPCR
showing the levels of miR-148a-3p upon METTL1 KD in A549 cells. The average of five independent biological replicates ±
S.D. is shown. G, Western blot of DICER, DGCR8 and ARGONAUTE (pan-AGO) upon METTL1 KD in A549 cells. H, Box
plots visualizing the normalized smallRNA-Seq counts of INPUT and m7G-RIP miRNAs from either control (Scr) or METTL1
KD A549 cells.  I, m7G RNA immunoprecipitation and RT-qPCR of  LET7A3,  LET7B,  LET7E/125A  and MIR23B primary
transcripts in A549 cells.  MIR148A is shown as a negative control.  J, m7G-RIP and RT-qPCR of  MIR23B and MIR148A
primary transcripts upon  METTL1 KD in A549 cells. The average of three independent biological replicates ± S.E.M. is
shown (*P<0.05, **P<0.01, ***P<0.001, two tailed t-test).
Figure S5
Figure S5 | METTL1-mediated miRNA methylation. Related to Figure 4 and 5. 
A, Autoradiography and digital  quantification of  the results from in vitro processing of  a radioactively labelled  pri-let-7e
incubated with cell extracts from control (Ctrl) or METTL1 KD A549 cells. The average of three independent experiments ±
S.D. is shown (*P<0.05, **P<0.01, two tailed t-test). Autoradiography images are composite of different molecular weight
regions  and  exposure  times.  Full,  unprocessed  images  are  deposited  on  Mendeley  Data.  B, Coomassie  staining  and
Western blot of co-expressed recombinant 6xHis-tagged METTL1 and FLAG-tagged WDR4 from baculovirus-infected insect
cells. C, In vitro methylation reaction using recombinant METTL1/WDR4 pre-assembled complex on pre-tRNAPhe or a hairpin
shRNA targeting GFP (negative control). Mass spectrometry analysis shows specific m7G methylation of pre-tRNA Phe. D,E,
Representative extracted ion chromatograms of collated charge states of unmodified (left chromatogram) and methylated
AGGAGGU (right chromatogram) oligonucleotides. Precursor ion areas were quantified from technical triplicates (quantified
area shown in grey). Chromatograms shown are from a single replicate.  E, in vitro methylation reaction using recombinant
METTL1/WDR4 pre-assembled complex on WT and G11-DAG let-7 oligonucleotides.
Figure S6
Figure S6 | m7G modified miRNAs are prone to G-quadruplex formation. Related to Figure 5. 
A, Box plot showing the base content in primary hairpins of either unmodified or m7G containing miRNAs (P-values are
calculated with Wilcoxon test).  B, Proportion of  G-quadruplex forming motifs detected within  primary hairpins of  either
unmodified or m7G containing miRNAs (see STAR Methods for details; *P<0.05, **P<0.01, ***P<0.001; Fisher’s exact test).
C, Circular dichroism (CD) of the minimal rG4-let-7e sequence reveals that its structure is cation-dependent and its spectra
display a minimum and maximum at 240 and 263 nm, respectively. These are feature of  G-quadruplex formation. The
stability of rG4-let-7e WT structure is cation-dependent, with a thermal stability (Tm) of 48.1 °C in the presence of 100 mM
KCl. While G11 to DAG substitution in rG4-let-7e DAG does not completely abolishes rG4 formation, it greatly destabilizes it.
The thermal stability decreases from 48.1 °C to 35.5 °C in the presence of 100 mM KCl and the oligonucleotide is no longer
folded in the presence of LiCl or NaCl. D, CD spectra of pri-let-7e hairpin. The minimum at 210 nm indicates the expected
stem-loop structure. E, Cartoon depicting the pri-miRNA hairpins employed in the following panel. F, Thermal denaturation
studies of GG to AA mutants at the D1 or D2 position, supporting the formation of a G-quadruplex within pri-let-7e. Melting
profiles of both mutants display a single transition at high temperature characteristic of the canonical hairpin structure. The
transition attributed to the rG4 motif is no longer observed. Both mutations destabilize the hairpin structure as expected
(decreased GC content). 
shRNA sequences
Scramble shRNA
Cloning Primers
Fw GTAGGCGGCCGCACCATGGCAGCCGAGACTCGGA
Rev CACTGTCTAGATCAGTGACCAGGCAGGCTGG
Gene Synthesis sequences
qPCR Taqman Primers
Primer Sequence Universal ProbeLibrary Number (Roche Cat# 4683633001)
Table S8
Table S8 | DNA and RNA oligonucleotides employed in this study. Related to STAR Methods
GAPDH Fw
TCCACTGGCGTCTTCACC
45Rv GGCAGAGATGATGACCCTTTT
HMGA2 Fw
ACCATTTCTGCAAGTTAGGTATGTT
2Rv GAACAGGGAGAAAGTCAACTGC
IL11 Fw
GGTGCATCTGTGGATAGAACG
28Rv TCCTTAGCCTCCCTGAATGA
qPCR Sybr Green Primers
Primer Sequence
LET7A3 Fw
GGGTGAGGTAGTAGGTTGTATAG
Rv TATAGTTATCCCATAGCAGGGCAGA
LET7B Fw
CGGGGTGAGGTAGTAGGTTGT
Rv CAGGGAAGGCAGTAGGTTGTATAG
LET7E/125A Fw
GGGCTGAGGTAGGAGGTTGT
Rv GGGAAAGCTAGGAGGCCGTA
MIR23B Fw
TGGCATGCTGATTTGTGACT
Rv GTGGTAATCCCTGGCAATGT
MIR148A Fw
GGCAAAGTTCTGAGACACTCC
Rv TTCTGTAGTGCACTGACTTCTATCA
pre-let-7e Fw
TGTATAGTTGAGGAGGACACCC
Rv GCTAGGAGGCCGTATAGTGA
pre-miR-125a Fw
TCCCTGAGACCCTTTAACCT
Rv CAAGAACCTCACCTGTGACC
pre-miR-148a Fw
GGCAAAGTTCTGAGACACTCC
Rv TTCTGTAGTGCACTGACTTCTATCA
RNY1 Fw
GCTGGTCCGAAGGTAGTGAG
Rv GGGGGAAAGAGTAGAACAAGG
qPCR Taqman Advanced miRNA Assay Ids (Thermo Fisher Cat# A25576)
hsa-let-7e-5p 478579_mir
hsa-miR-125a-5p 477884_mir
hsa-miR-196a-5p 478230_mir
hsa-miR-375 478074_mir
hsa-miR-148a-3p 477814_mir
hsa-miR-381-3p 477816_mir
hsa-mir-101-3p 477863_mir
RNA Oligonucleotides
pre-Phe-tRNA GCGGAUUUAGCUCAGUUGGGAGAGCGCCAGACUGAAGAAAAAACUUCGGUCAAGUUAUCUGGAGGUCCUGUGUUCGAUCCACAGAAUUCGCACCA
cel-miR-67 CGUCGAUCCGCUCAUUCUGCCGGUUGUUAUGCUAUUAUCAGAUUAAGCAUCACAACCUCCUAGAAAGAGUAGAUCGAUU
pri-let-7e WT CCCGGGCUGAGGUAGGAGGUUGUAUAGUUGAGGAGGACACCCAAGGAGAUCACUAUACGGCCUCCUAGCUUUCCCCAGG
pri-let-7e AAmutD1 CCCGGGCUGAAAUAGGAGGUUGUAUAGUUGAGGAGGACACCCAAGGAGAUCACUAUACGGCCUCCUAGCUUUCCCCAGG
pri-let-7e AAmutD2 CCCGGGCUGAGGUAGGAAAUUGUAUAGUUGAGGAGGACACCCAAGGAGAUCACUAUACGGCCUCCUAGCUUUCCCCAGG
CCCGGGCUGA**UAGGAGGUUGUAUAGUUGAGGAGGACACCCAAGGAGAUCACUAUACGGCCUCCUAGCUUUCCCCAGG
CCCGGGCUGAGGUAGGA**UUGUAUAGUUGAGGAGGACACCCAAGGAGAUCACUAUACGGCCUCCUAGCUUUCCCCAGG
CCCGGGCUGAGGUAGGA*GUUGUAUAGUUGAGGAGGACACCCAAGGAGAUCACUAUACGGCCUCCUAGCUUUCCCCAGG
rG4-let-7e WT GGGCUGAGGUAGGAGG
GGGCUGAGGUAGGA*G
METTL1 sh1 CCGGGATGACCCAAAGGATAAGAAACTCGAGTTTCTTATCCTTTGGGTCATCTTTTTG
METTL1 sh2 CCGGCCCACATTTCAAGCGGACAAACTCGAGTTTGTCCGCTTGAAATGTGGGTTTTTG
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTTG
METTL1 cDNA
METTL1 WT
CACACTGGCGGCCGCACCATGGCAGCCGAGACTCGGAACGTGGCCGGAGCAGAGGCCCCACCGCCCCAGAAGCGCTACTACCGGCAACGTGCTCACTCCAACCC
CATGGCGGACCACACGCTGCGCTACCCTGTGAAGCCAGAGGAGATGGACTGGTCTGAGCTATACCCAGAGTTCTTCGCTCCACTCACTCAAAATCAGAGCCACG
ACGATCCTAAAGACAAAAAAGAAAAGAGAGCTCAGGCCCAAGTGGAGTTTGCAGACATAGGCTGTGGCTATGGTGGCCTGTTAGTGGAACTGTCACCGCTGTTC
CCAGACACACTTATTCTGGGTCTGGAGATCCGGGTGAAGGTCTCAGACTATGTACAAGACCGGATTCGGGCCCTACGCGCAGCTCCTGCAGGTGGCTTCCAGAA
CATCGCCTGTCTCCGTAGCAATGCCATGAAGCACCTTCCTAACTTCTTCTACAAGGGCCAGCTGACAAAGATGTTCTTCCTCTTCCCCGATCCCCACTTTAAAC
GCACAAAGCACAAGTGGCGAATCATCAGTCCCACCCTGCTAGCAGAAT
METTL1 EIR/AAA Mut
CACACTGGCGGCCGCACCATGGCAGCCGAGACTCGGAACGTGGCCGGAGCAGAGGCCCCACCGCCCCAGAAGCGCTACTACCGGCAACGTGCTCACTCCAACCC
CATGGCGGACCACACGCTGCGCTACCCTGTGAAGCCAGAGGAGATGGACTGGTCTGAGCTATACCCAGAGTTCTTCGCTCCACTCACTCAAAATCAGAGCCACG
ACGATCCTAAAGACAAAAAAGAAAAGAGAGCTCAGGCCCAAGTGGAGTTTGCAGACATAGGCTGTGGCTATGGTGGCCTGTTAGTGGAACTGTCACCGCTGTTC
CCAGACACACTTATTCTGGGTCTGGCGGCAGCCGTGAAGGTCTCAGACTATGTACAAGACCGGATTCGGGCCCTACGCGCAGCTCCTGCAGGTGGCTTCCAGAA
CATCGCCTGTCTCCGTAGCAATGCCATGAAGCACCTTCCTAACTTCTTCTACAAGGGCCAGCTGACAAAGATGTTCTTCCTCTTCCCCGATCCCCACTTTAAAC
GCACAAAGCACAAGTGGCGAATCATCAGTCCCACCCTGCTAGCAGAAT
pri-let-7e D1 (*=DAG)
pri-let-7e D2 (*=DAG)
pri-let-7e G11 (*=DAG)
rG4-let-7e DAG (*=DAG)
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BoRed-Seq Protocol
1 RNA extraction from A549 cells
Total RNA, including miRNAs, is extracted from mammalian cells. To ensure optimal results, it is
advisable to always start with freshly extracted RNA.
1. Culture up to 1.5×107 A549 cells to a confluency of ∼80%.
2. Remove the medium and rinse the cells twice in PBS.
3. Extract RNA using the miRNeasy Mini Kit (Qiagen). Elute RNA in 30 µl RNAse-free water.
2 RNA decapping
Cap-Clip Acid Pyrophosphatase is used to remove the m7GpppG cap of eukaryotic mRNA in order to
avoid cross-reactivity to non-internal m7G.
1. Prepare the RNA decapping mix according to Table 1.
2. Incubate for 1 h at 37℃.
3. Purify RNA using the RNA Clean and Concentrator - 25 Kit (Zymo Research).
Table 1: Reaction mix for RNA decapping for ∼20µg total RNA
Volume Reagent
20 µg RNA
2 µl 10× Reaction buffer
1 µl CapCLIP (5U; CellScript)
1 µl RNAsin Plus (Thermo Fisher)
20µl Final vol. with ddH2O
3 NaBH4 Reduction
m7G residues are specifically reduced by treatment with NaBH4 in the presence of high concentrations
of free m7GTP. Control samples are treated with acid-quenched NaBH4. The NaBH4 treatment also
reduces aldehydes in RNA (e.g. 5-formylcytosine or 5-formyluracil), thereby preventing unwanted
covalent binding of ARP with them in the downstream stages.
1. Throughout the entire protocol, always use nuclease-free not DEPC-treated water (Ambion) as
even small traces of DEPC lead to RNA degradation after NaBH4 reduction.
2. Prepare 3M Tris-HCl (pH 8.2) and 1M sodium acetate (NaOAc; pH 4.5). Filter through
0.22 µm filter and autoclave. Store aliquots at -20℃.
3. Prepare the RNA mix according to Table 2. For each sample prepare n×2 reaction mixes: one
reduction reaction (red) and one control reaction (ctrl). At least three parallel reactions are
recommended to obtain sufficient reduced RNA for subsequent steps.
4. Prepare a fresh 1M sodium borohydride solution (NaBH4; Sigma-Aldrich) immediately before
use. The NaBH4 powder should be stored at 4 ◦C in a desiccator.
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Table 2: Reaction mix for 4 µg of RNA
Volume Reagent
up to 4µg RNA
3 µl 37mM m7GTP (Sigma-Aldrich)
5 µl 3M Tris-HCl (pH 8.2)
15 µl Final vol. with ddH2O
5. Add 15 µl 1M NaBH4 solution to the reduction reaction. Vortex and spin briefly. Do not add
NaBH4 to the ctrl reaction and keep it on ice until quenching.
6. Incubate on ice for 40min. Open the lid of the tube, debubble and spin down every 10min.
7. Meanwhile prepare the quenched NaBH4 solution (QB1) for the control reaction (non-reduced
RNA) according to Table 3.
8. Incubate QB1 at 90 ◦C for 30min.
9. Place QB1 on ice and add 1 µl of glycogen (20 µg/µl; Roche).
Table 3: Preparation of QB1 solution
Volume Reagent
180 µl 1M NaOAc (pH 4.5)
120 µl ddH2O
15 µl 1M NaBH4
Table 4: Preparation of QB2 solution
Volume Reagent
180 µl 1M NaOAc (pH 4.5)
120 µl ddH2O
1 µl 20µg/µl glycogen
10. Prepare the quenching solution for the reduction reaction (QB2) according to Table 4. Keep it
on ice until used.
11. After the incubation of the reduction reaction (red) on ice for 40min, add 300 µl of QB2
quenching solution drop-wise, to avoid a violent reaction.
12. Add 990 µl of ice-cold absolute ethanol.
13. Add 315 µl of QB1 solution and 990 µl of ice-cold absolute ethanol to the control reaction
(ctrl).
14. Incubate both reactions (red and ctrl) for 1 h at -20 ◦C to precipitate RNA.
15. Centrifuge at ≥15,000 g for 30min at 4 ◦C. Carefully decant the supernatant.
16. Wash the RNA with 1ml of 70% ethanol. Vortex to detach the pellet for 5min at room
temperature.
17. Centrifuge at ≥15,000 g for 5min at 4 ◦C.
18. Carefully remove the supernatant and air-dry the pellet.
19. Dissolve the pellet in 10 µl ddH2O and quantify by Qubit RNA HS Assay (Thermo Fisher).
4 RNA abasic site production
The reduced m7G residues are subjected to nucleoside hydrolysis at low pH.
1. Prepare a sodium acetate solution (pH 3.9) by mixing 3.5ml ddH2O, 1.5ml acetic acid and
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300 µl 10N sodium hydroxide (NaOH).
2. Add 1 µl 7-methyl-GTP (37mM; Sigma-Aldrich) and 11 µl of acetate solution to the RNA
dissolved in 10 µl of ddH2O (ctrl or red).
3. Incubate the mix for 15min at 37 ◦C.
4. Precipitate by adding 200 µl ddH2O, 20 µl NaOAc (pH 4.5), 660 µl of ice-cold absolute ethanol
and 1 µl glycogen.
5. Incubate for 1 h at -20 ◦C.
6. Centrifuge at ≥15,000 g for 30min at 4 ◦C. Carefully decant the supernatant.
7. Wash the RNA with 1ml of 70% ethanol. Vortex to detach the pellet.
8. Centrifuge at ≥15,000 g for 5min at 4 ◦C.
9. Carefully remove the supernatant and air-dry the pellet.
10. Dissolve the pellet in 10 µl ddH2O and quantify by Qubit RNA HS Assay.
5 ARP coupling and pulldown
A biotin-coupled aldehyde reactive probe covalently binds to the abasic RNA sites resulting from m7G
reduction and hydrolysis. This allows pull-down with streptavidin-conjugated beads.
1. Prepare a 22.5mM stock solution (4.5×) of Aldehyde Reactive Probe (ARP) by adding 1ml
ddH2O to 10mg of ARP powder (N-(aminooxyacetyl)-N’-(D-Biotinoyl) hydrazine, Trifluoroacetic
Acid Salt; Thermo Fisher).
2. Prepare the 10×Reaction buffer containing 50mM Tris-HCl (pH 6.8) and 10mM EDTA.
3. Denature the RNA at 80 ◦C for 2min.
4. Incubate RNA on ice for 5min.
5. Prepare the ARP reaction according to Table 5.
Table 5: Preparation of ARP reaction mix
Volume Reagent
4.5 µg RNA (crtl or red)
8 µl 22.5mM ARP (3mM final)
6 µl 10×Reaction buffer
60 µl Final vol. with ddH2O
Table 6: Preparation of pulldown reaction
Volume Reagent
2-3 µg total RNA
200 µl 5×PD buffer
1ml Final vol. with ddH2O
6. Incubate for 1 h at 30 ◦C.
7. Meanwhile prepare 1.33M formaldehyde solution in water (dilution of 1:10 from 37% formalde-
hyde stock; Sigma-Aldrich).
8. To stop the reaction, add 2.25 µl 1.33M formaldehyde solution, then add 40 µl ddH2O,
10 µl 3M sodium acetate and 300 µl absolute ethanol to the ARP samples.
9. Precipitate RNA at -20 ◦C for 1 h.
10. Pellet RNA by centrifugation at ≥15,000 g for 30min at 4 ◦C.
11. Decant supernatant carefully and wash the pellet twice with 70% ethanol (step 7 of section 4).
12. Dissolve RNA in 50 µl ddH2O.
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13. Filter through an Illustra MicroSpin G-25 spin column (GE Healthcare) to remove the remaining
unreacted ARP.
14. Prepare the 5×Pulldown (PD) buffer containing 50mM Tris-HCl (pH 7.4), 750mM sodium
chloride (NaCl) and 0.5% NP-40 (v/v).
15. Wash 50 µl of Dynabeads MyOne C1 Streptavidin beads (Thermo Fisher) three times with 1×
PD buffer.
16. Resuspend the beads in 1ml 1×PD buffer + 0.5mg/ml BSA (NEB).
17. Incubate for 1 h at 4 ◦C in rotation.
18. Prepare the PD reaction according to Table 6.
19. Add the blocked beads to the PD reaction.
20. Incubate at room temperature for 25min in rotation.
21. Wash four times with ice-cold 1× PD buffer.
22. Add 700 µl QIAzol (Qiagen) and 140 µl chloroform to the beads.
23. Purify using the RNA Clean and Concentrator - 25 Kit (Zymo Research) according to the
manufacturer’s instructions.
24. Elute in 10-15 µl ddH2O and quantify by Qubit RNA HS Assay.
6 7-Methylguanosine RNA Immunoprecipitation
Heat-denatured RNA is immunoprecipitated with a specific antibody against m7G. Both Input and IP
samples are then purified using the same strategy in order to avoid any bias.
1. Denature decapped RNA for 2min at 80 ◦C and place immediately on ice.
2. Save a 1-2.5 µg aliquot of RNA as INPUT control.
3. Prepare the 5×RIP buffer according to Table 7.
4. Prepare the RIP reaction according to Table 8.
5. Incubate the RIP reaction for 2 h at 4 ◦C in rotation.
Table 7: Preparation of 5×RIP reaction buffer
Volume Reagent
0.5ml 1M Tris-HCl (pH 7.4)
1.5ml 5M NaCl
0.5ml 10% NP-40 (v/v)
7.5ml ddH2O
Table 8: Preparation of RIP reaction
Volume Reagent
25 µg total RNA
10 µg anti-m7G antibody (RNO17M)
10 µl RNAseOUT (Thermo Fisher)
200 µl 5×RIP buffer
1 ml Final vol. with ddH2O
6. Wash n×80 µl Dynabeads G (Thermo Fisher) twice with 1ml 1×RIP buffer.
7. To block the Dynabeads, resuspend them in 1ml 1×RIP buffer and add 50 µl 20 µg/µl BSA
(NEB), then incubate for 2 h at 4 ◦C in rotation.
8. Wash the beads twice with 1×RIP buffer and resuspend them in n×100 µl 1×RIP buffer.
9. Add 100 µl beads to each RIP reaction.
10. Incubate for 2 h at 4 ◦C in rotation.
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11. Wash three times with 1ml ice-cold 1×RIP buffer, changing the 1.5ml tube in the first wash.
12. Resuspend the beads in 100 µl 1×RIP buffer + 2 µl RNAseOUT (Thermo Fisher) + 6.7mM
7-methyl-GTP (Sigma-Aldrich).
13. Incubate for 30min at 37 ◦C to specifically elute m7G-harbouring RNAs, then collect the
supernatant.
14. Bring the volume of the INPUT RNA control to 100 µl in 1×RIP buffer + 2 µl RNAseOUT +
6.7mM 7-methyl-GTP.
15. Purify both INPUT and RIP samples with the RNA Clean and Concentrator - 25 Kit.
16. Elute in 10-15 µl ddH2O and quantify by Qubit RNA HS Assay.
7 SmallRNA Sequencing Library Preparation
Sequencing libraries are prepared from resulting BoRed or m7G-RIP RNA with a commercial kit
optimized to generate size-selected Small RNA libraries.
Prepare high-throughput libraries using NEBNext Small RNA Library Preparation kit for Illumina
(NEB) starting from 1 µg of RNA for each sample and employing gel extraction as the final purification
step, according to the manufacturer’s protocol.
8 High Throughput Sequencing
Multiplexed libraries are sequenced by high-throughput sequencing-by-synthesis (Illumina).
Sequence the pooled libraries on Illumina platform running in 50-bp single-read mode. Plan the
multiplexing strategy in order to get at least 15-20M raw reads per sample for BoRed-Seq and 5-10M
reads for m7G-RIP.
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